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General introduction and outline of this thesis
Colorectal cancer is one of the most common tumor types and a leading cause of death worldwide. In 
the Netherlands approximately 9900 colorectal carcinomas were diagnosed in 2003 and this cancer 
was the cause of death in 4400 patients [www.ikcnet.nl]. Metastatic disease of the liver will eventually 
occur in up to 40% of patients with colorectal carcinoma. Without any treatment median survival of 
metastatic colorectal liver disease is approximately nine to twelve months 1. 
Especially when metastases are confined to the liver, resection is the treatment option of first choice 
and can be performed with curative intent. Five years survival rates varying from 23 up to 51 % are 
described and a ten-year survival of 28% was recently published 2-3. 
Unfortunately only 10-15% of patients with metastatic disease are candidate for resection. A number 
of alternative treatment modalities can be applied in case of irresectable colorectal metastases or in 
patients unfit to undergo hepatic surgery.
Several chemotherapeutic regimens can be offered in case of colorectal metastases. In the last 
ten years, with the development of new cytotoxic agents and biological monoclonal antibodies, 
disease free and overall survival rates have changed dramatically. As ten years ago 5-FU/leucovorin 
was the only slightly effective agent, today the introduction of new cytotoxic drugs like irinotecan 
and oxaliplatin has made a progress in treatment of metastatic colorectal disease. Next to that the 
addition of biologicals, like bevacizumab, has led to median survival rates of about 20 months 4. 
Also other treatment options have emerged. Especially in case of limited irresectable disease the 
need for a more definitive and possible curative treatment has led to the development of several 
ablative techniques. In the past cryosurgery has proven to be a relatively safe and effective local 
tumor ablative technique 5-7. Less common used techniques with variable results in different series 
are percutaneous ethanol injection (PEI), transarterial chemoembolization (TACE) and laser induced 
thermotherapy (LITT) 8-10. Among all local ablative techniques, radiofrequency ablation (RFA) is the 
most widely used technique. The technique itself is relatively easy to perform and morbidity is low 
11-13. 
The basic idea behind local tumor ablation is to selectively destruct tumor tissue (including a rim of 
normal tissue around the tumor) without significant damage to vascular structures in the remaining 
liver and hence consequent loss of large areas of normal liver tissue. This local tumor destruction can 
be achieved by application of extreme cold or heat.
Already in ancient Egypt and Greece the therapeutic properties of extreme cold and heat were 
understood and used in the treatment of several diseases 14. In the mid 19th century, James Arnott 
was one of the first to use the application of extreme cold for destruction of tissue and around 1910 
Beer and Clark described the use of radiofrequency current in the treatment of cancer 15-16.
Next to tumor destruction, local ablative techniques could also sort an immunological effect. In the 
early days of cryosurgery clinical observations were made suggesting an anti-tumor response after 
cryosurgery. Reduction of pulmonary metastases after cryosurgical treatment of a primary prostate 
carcinoma was reported 17-18. Hereafter numerous experimental animal studies were conducted to 
further investigate this possible immune response. Some groups believed that lymphocyte-mediated 
cytotoxicity was responsible for a possible anti-tumor response, while others reported on a more or 
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less aspecific inflammatory response 19-21. On the other hand some experimental studies describe an 
enhancing effect on tumor growth after cryosurgery 22. After cryosurgery, in both experimental as 
well as clinical studies, elevation of cytokines like IL-1, IL-6, and TNF is described. According to some 
reports the release of these cytokines could explain the cryoshock phenomenon that is characteristic 
for cryoablation 23-24. Exclusive data on the possible immuno-modulating effects of these cytokines 
have yet to be established, but could give rise for possible cryo- and/or RFA immunotherapy as is 
already explored in an animal model 25. 
The scope of this thesis is to describe the possibilities of mainly surgical forms of local ablative 
treatment of colorectal liver metastases and its results. Also the results of a specific group of patients 
which developed pulmonary metastases after earlier hepatic resection are described. Next to that a 
start was made with an experimental animal model to gain more insights on the possible immunologic 
consequences of local ablative therapies.
In chapter 2 cryosurgical ablation is described: its history, indications, the technique itself and a review 
of results in literature. Cryosurgery should be regarded as a complement to hepatic resection in case 
of irresectable disease. Median survival exceeds two years and seems superior over chemotherapy, 
although these results could be due to patient selection.
In chapter 3 the technique of radiofrequency ablation is extensively described. In a review article its 
indications, complications, results and limitations are mentioned. RFA seems safe and feasible and 
proofs to be effective in local tumor control. Also for RFA results seem to be favorable when compared 
to chemotherapy, but again this vision could be blurred by patient selection. Recommendations are 
made to conduct and participate in trials comparing RFA with chemotherapy. Chapter 4 provides our 
results in patients treated by cryosurgery. The procedure shows an acceptable complication rate. A 
median survival rate of 32 months was observed and disease free survival after one year was 35 percent. 
Local recurrence at the treated site was 9%. In chapter 5 the results of cryosurgery are compared with 
the results of RFA. Survival rate and disease free survival are comparable. An advantage of RFA over 
cryosurgery seems to be its lower complication rate.
Chapter 6 describes a comparison between local ablative therapy and chemotherapy for non-
resectable colorectal liver disease. Median survival was not significantly different, but a disease 
free survival of nine months in the RFA group suggests a beneficial effect of local tumour ablation. 
Moreover, compared with chemotherapy more quality adjusted life years were gained after local 
ablative therapy.
In chapter 7 the results are presented of patients who underwent pulmonary resection of colorectal 
metastases with a fairly unique subgroup of patients who underwent earlier hepatic metastasectomy 
or ablation. Five year survival after resection of pulmonary metastases after earlier surgery for hepatic 
metastases is about 20 %. It seems that a selected group of patients benefits from an aggressive 
surgical approach to liver and pulmonary metastases.
Chapter 8 describes the effect of local tumor ablation on residual tumor growth in a mouse model. 
Cryosurgery of a tumor leads to inhibition of secondary and metastatic tumor growth as compared to 
excision. An evident cytokine response after cryoablation is noticed and may attribute to this feature. 
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In chapter 9 the inflammatory response after cryosurgery is further investigated in an experimental 
mouse model. The findings are in accordance with the clinical observation of cryoshock: a multi organ 
failure syndrome which can occur after cryoablation. 
In chapter 10 and 11 the results and conclusions are summarized.
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Cryosurgery in the treatment of colorectal liver metastases
Abstract
Liver metastases occur in about 40% of patients with colorectal cancer. Until now liver resection 
is considered to be the only treatment that may result in definite cure. However, only a minority of 
patients are eligible to undergo resection. 
Cryoablative surgery has emerged as a therapeutic option in the treatment of unresectable liver 
tumours. With subzero temperatures, applied to tumour tissues by sophisticated probes under 
ultrasonic guidance, adequate tumour destruction is possible. 
Several studies report one-year survival rates of more than 70% and 2-year survival rates of more than 
50%. Disease free survival at 2 years varies from 11 to 29%. 
Complications like chest problems, coagulopathy, abscess formation and haemorrhage may occur, but 
seem not to exceed complication rates as seen in liver resection.
To date, hepatic resection still remains the gold standard in the treatment of colorectal liver 
metastases. However, cryosurgery has proven to be an alternative for the treatment of unresectable 
colorectal liver metastases.
Introduction
A significant number of patients (40%) with colorectal cancer will eventually develop hepatic 
metastases. Although curative treatment by resection is possible, this option is only eligible in about 
15% of the patients. Therefore, other techniques to treat unresectable liver metastases have gained 
more and more interest. 
Already in the 19th century the application of extreme cold has been recognised as a possible 
treatment modality in cancer therapy. In time, cryosurgical treatment has proven to be an effective 
alternative to surgical resection and has been used at various anatomic sites such as skin, oral cavity, 
prostate and bone 1-5. 
Also destruction of liver tumours by the use of cryoablation has been attempted for a long time 
and early experiments made use of direct application of liquid nitrogen to superficial parts of the 
liver6,7. Clinical acceptance of the method, however, was limited by the inability to treat intrahepatic 
lesions.
Thanks to several technical developments, cryosurgery has been re-introduced in liver surgery. 
With the introduction of more sophisticated cryoprobes organs with high blood flow such as the 
liver became accessible for the application of below zero temperatures. Secondly, intra-operative 
monitoring of the freezing process has become more accurate allowing constant monitoring of the 
cryo procedure. 
Due to these developments, cryosurgery has emerged as a treatment modality for patients with 
unresectable liver tumours. The method has shown to be feasible and safe in the treatment of 
one or more unresectable tumour deposits within the liver 8-19. While most studies published on 
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cryoablation focus on feasibility and safety, there are only a few publications with long-term results 
after cryosurgery. Studies comparing cryosurgery for unresectable colorectal liver metastases with 
chemotherapy or other in situ ablative techniques, such as radiofrequency tumour destruction, have 
yet to be established. 
Tissue destruction by cryoablation
In hepatic cryosurgery, cooled probes with liquid nitrogen are placed into the tumour lesions. A 
combination of factors will eventually lead to cell death 20,21. During the freezing process intracellular 
ice crystal formation results in cell death due to water extraction leading to accumulation of 
intracellular electrolytes. Intracellular ice formation occurs close to the cryoprobe where freezing 
is fast and temperatures are low. At the edge of the tumour where freezing rates are slower, extra 
cellular ice formation will take place, resulting in cellular dehydration, microvascular thrombosis and 
finally cell death. 
Experimental studies have shown that maximum cell death occurs at fast or slow freezing rates; 
maximum survival of cells is seen at moderate cooling rates 22,23. Moreover, slow thawing at room 
temperature enhances effective tumour cell destruction. Clinically at least two freeze thaw cycles 
are being performed to ensure maximum cell death and to obtain optimal tumour cell destruction in 
the entire tumour lesion.
Technique of cryoablation
The liver is exposed after opening of the abdomen through a subcostal incision. Next, the number and 
localization of metastases is determined by the use of intraoperative ultrasonography. A decision is 
made whether unresectable lesions can be treated radically by cryosurgery.
When complete treatment of the unresectable lesions is judged possible the cryoprobes should 
be placed centrally in the tumour lesion under ultrasonic guidance. In case of large lesions several 
probes should be introduced into the tumour. Applying a flat cryoprobe directly to the lesion may 
treat superficial lesions.
After accurate positioning of the cryoprobe(s) liquid nitrogen is driven through the probe at -196°C 
leading to a probe tip temperature of -190°C to -180°C 24. During the freezing process ultrasonic 
monitoring is carried out to visualise the formation of an ice ball. To ensure adequate freezing of all 
tumour cells it is essential that the ice ball includes the entire tumour lesion and a rim of normal liver 
tissue as well. After about 15-20 minutes the entire tumour will be frozen and subsequently thawing 
of the tumour is allowed. To increase cell kill in the target area a second freeze-thaw cycle is generally 
performed. At the end of the procedure when the tumour is thawed the probe is removed and the 
entry site is filled with surgical sealant.
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Large blood vessels and hence high flow may cause a heat sink phenomenon resulting in less efficient 
freezing. Inflow occlusion of the liver (Pringle manoeuvre) may overcome this phenomenon but on 
the other hand increases the risk of serious bleeding. 
In several institutions some experience has been gained with a laparoscopic as well as a percutaneous 
approach for cryoablation of liver tumours 25-29. 
Complications of cryoablation 
Most series on cryosurgery report a mortality rate below 5% 8-15,30. Acute post-operative myocardial 
infarction is the most common cause of death followed by cryoshock and pulmonary complications. 
Pulmonary complications such as chest infection and atelectasis occur in up to 25% of the cases 
and are generally related to upper abdominal surgery. Pleural effusion is more often encountered, 
but is generally transient and does not require drainage15. Haemorrhage during or after the freezing 
process is seen in up to 9% of the cases and is mostly caused by cracking of the ice ball. Especially 
when the liver surface is frozen the risk of cracking occurs. Other factors that contribute to hepatic 
cracking are large size of the frozen area, multiple ice balls adjacent to each other, and movement of 
the cryoprobe during the procedure. In most cases bleeding can be controlled by applying pressure 
and suturing. 
Damage to the bile ducts may occur when freezing is performed close to a main bile duct. Formation 
of bilomas is described in up to 8% of the patients. Abscess formation in the cryo area is observed in 
about 2% of the cases. Percutaneous drainage is usually sufficient to overcome these complications. 
In some patients acute tubular necrosis has occurred which is mainly caused by myoglobinuria 31. This 
complication can be prevented by vigorous alkalisation of the urine. Also coagulopathy as seen by 
decreasing platelet count may occur after cryosurgery. This phenomenon is usually transient. Follow 
up of platelet count and other parameters of coagulopathy is advisable, but correction by means of 
platelet administration or full frozen plasma is only occasionally needed. 
A rare, but life threatening feature is the phenomenon of cryoshock which occurs in about 1 percent 
of the patients and accounts for about 18% of all mortality after cryosurgery 30.
Survival
Despite the fact that cryosurgery has been used now for many years, the effect of the treatment 
on overall survival is still difficult to asses. Tumour characteristics, patient selection and treatment 
strategies using cryosurgery vary considerably between most studies which hamper comparison 
of treatment results significantly 8-19,32. Moreover, randomised studies comparing cryosurgery with 
resection for resectable disease or cryosurgery with chemotherapy for unresectable disease are still 
lacking. These limitations should be faced when analysing the results of cryotreatment on survival. 
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With regard to colorectal liver metastases, cryosurgery has mainly been used for the treatment 
of unresectable disease (table 1). Two large series on cryosurgery for unresectable colorectal liver 
metastases have been published. Weaver et al. reported on 136 patients with unresectable colorectal 
liver metastases varying in number from 1 to 10 12. The 2- and 5-year survival rates in the study were 
62% and 20% respectively, the median survival 30 months. Seifert et al. published data on the long-
term outcome of 116 patients with colorectal liver metastases treated by cryosurgery in combination 
with intra-arterial chemotherapy 14. The 2- and 5-year survival rates were respectively 56% and 13%. 
The results for patients with small liver metastases were superior to those with large metastases. 
The 2-year survival rate for patients with metastases smaller or equal to 2 cm was 70% versus 31% 
for patients with metastases larger than 5 cm. Also, patients that were operated radically showed 
a significant better 2-year survival (63%) than patients with residual tumour (38%) at the time of 
surgery. In contrast to the study by Weaver et al, patients received an arterial access system into the 
hepatoduodenal artery for postoperative chemotherapy. Earlier studies by this group had shown a 
significant beneficial effect of this approach. In a limited number of patients (n=38) the estimated 
median survival of patients treated with cryotherapy alone was 245 days compared to 570 days for 
those patients treated by a combined approach of cryotherapy plus post operative intra-arterial 
chemotherapy 13. 
Table 1   Survival after cryosurgery for unresectable colorectal liver metastases
Author No. of patients 1-year survival 2-year survival 5-year survival 
Weaver, 1998 (12) 136 82% 62% 20%
Seifert, 1998 (14) 116 82% 56% 13%
Ruers, 2001 (32) 30 76% 61%
Crews, 1997 (11) 27 80% 50%
Adam, 1997 (10) 25 77% 52%
Shafir, 1996 (9) 25 72% 65%
Haddad, 1998 (19) 24 59% 33%
In order to reduce tumour mass preoperatively, Adam et al. combined cryosurgery with preoperative 
chemotherapy 10. Twenty-five patients with unresectable colorectal liver metastases were treated 
by intensive chemotherapy followed by cryosurgery with or without additional hepatic resection 
or resection of extra-hepatic disease. In this study 1- and 2-year survival rates were 77% and 52% 
respectively. As also observed by Seifert, a small diameter (≤ 3 cm) of the treated lesions and complete 
cryoablation of the lesions resulted in a more favourable prognosis.
From the studies published thus far the most successful approach seems to resect all resectable 
lesions and to perform cryosurgery for those lesions that cannot be resected. The fact that this 
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approach may be the most successful was also suggested by a small study by Johnson et al in which 
patients treated by cryosurgery plus resection showed a better outcome compared to patients with 
comparable liver involvement that were treated by cryosurgery alone 16. In our own series on patients 
with unresectable colorectal liver metastases this combined approach resulted in a 1- and 2-year 
survival rate of 76% and 61% respectively 32. Recently, Finlay et al. even reported that resection of 
resectable lesions and cryosurgery of the remaining unresectable liver lesions or of tumour positive 
resection margins resulted in the same survival as hepatic resection alone 33. Moreover, this group 
clearly showed that elevated CEA levels that returned to normal levels after cryoablation were highly 
indicative for complete treatment and favourable prognosis 34.
Although some patients may be cured after cryosurgery far most patients will encounter recurrent 
disease. Disease free survival after 2 years varies in different series between 11 and 29% 8,10,11,17,18. This 
may not be surprising since patient selection is generally unfavourable. Most patients have extensive 
liver disease and hence after treatment may have a high chance of extra-hepatic recurrence or liver 
recurrence outside the treated area. Extra-hepatic sites are involved in 40-60% of the patients with 
recurrent disease, hepatic recurrence is observed in 60-80% of the cases with recurrent disease.
Local recurrence, which should be interpreted as a direct failure of cryotherapy, is observed in 0-
22% of the cases 8,11,17,18,32. However, a local recurrence rate as high as 44% has been reported 10. Local 
recurrence is mostly due to large tumour size, inadequate ultrasound monitoring, the use of an 
inadequate probe diameter or cryotherapy of lesions situated close to large vessels. 
Conclusion
Hepatic resection remains the gold standard for the treatment of colorectal liver metastases. To date 
there is insufficient evidence that cryosurgery is equivalent to hepatic resection. Several studies, 
however, show that cryosurgery may be beneficial in unresectable colorectal liver metastases. In 
these patients cryosurgery should mainly be regarded as a compliment to hepatic resection in whom 
hepatic resection deals with the major tumour mass, while cryosurgery can be of help to treat residual 
tumour tissue that can not be resected. In this group of patients cryosurgery can result in a median 
survival of more than two years. These results are superior to chemotherapy in which median survival 
varies between 12 and 17 months depending on the chemotherapy regimen used. However, these 
superior results of cryo treatment may be due to patient selection. Though generally unresectable, 
patients who undergo cryo treatment normally show a limited number of metastatic deposits (less 
than 10). This in contrast to patients treated by chemotherapy who may show more widespread liver 
involvement or even extra-hepatic disease. Hence randomised studies comparing chemotherapy with 
cryosurgery or any other local tumour destructive therapy, like radiofrequency, are badly needed.
Joris Joosten.indb   23 13-11-2008   15:14:56
24
Chapter 2 
References
1. Gage AA. Cryosurgery in the treatment of cancer. Surg Gynecol Obstet 1992; 174: 73-92.
2. Blackwood J, Moore FT, Pace WG. Cryotherapy for malignant tumours. Cryobiology 1967; 4: 33-8.
3. Breitbart E. Cryosurgery in the treatment of cutaneous malignant melanoma. Clin Dermatol 1990; 8: 96-
100.
4. Wong WS, Chin DO, Chin J, Tom WL. Cryosurgery as a treatment for prostate cancer: results and complications. 
Cancer 1997; 79: 963-74.
5. Gill W, Long W, Fraser J, Lee P. Cryosurgery for neoplasia. Br J Surg 1970; 57: 494-502.
6. Hass GM, Taylor CB. Quantitative hypothermal method for production of local injury of tissue. Arch Pathol 
1948; 45: 563-80.
7. Bayjoo P, Jacob G. Hepatic cryosurgery: biological and clinical considerations. J R Coll of Surg Edinb 1992; 37: 
369-72. 
8. Ravikumar TS, Kane R, Cady B et al. A 5-year study of cryosurgery in the treatment of liver tumours. Arch 
Surg 1991; 126: 1520-4.
9. Shafir M, Shapiro R, Sung M et al. Cryoablation of unresectable malignant liver tumors. Am J Surg 1996; 171: 
27-31.
10. Adam R, Akpinar E, Johann M et al. Place of cryosurgery in the treatment of malignant liver tumors. Ann 
Surg 1997; 225:39-50.
11. Crews KA, Kuhn JA, McCarty TM et al. Cryosurgical ablation of hepatic tumors. Am J Surg 1997; 174: 614-8.
12. Weaver ML, Ashton JG, Zemel R. Treatment of colorectal liver metastases by cryotherapy. Sem Surg Oncol 
1998; 14: 163-70.
13. Preketes AP, Caplehorn JRM, King J et al. Effect of hepatic artery chemotherapy on survival of patients with 
hepatic metastases from colorectal carcinoma treated with cryotherapy. World J Surg 1995; 19: 768-71.
14. Seifert JK, Morris DL. Prognostic factors after cryotherapy for hepatic metastases from colorectal cancer. 
Ann Surg 1998; 228: 201-8.
15. Seifert JK, Junginger T, Morris DL. A collective review of the world literature on hepatic cryotherapy. J R Coll 
Surg Edinb 1998; 43: 141-3.
16. Johnson LB, Krebs TL, Van Echo D et al. Cytoablative therapy with combined resection and cryosurgery for 
limited bilobar hepatic colorectal metastases. Am J Surg 1997; 174: 610-3. 
17. Onik G, Rubinsky B, Zemel R et al. Ultrasound-guided hepatic cryosurgery in the treatment of metastatic 
colon carcinoma. Cancer 1991; 15: 901-7.
18. Weaver M, Atkinson D, Reuben Zemel et al. Hepatic cryosurgery in treating colorectal metastases. Cancer 
1995; 76: 210-4.
19. Haddad FF, Chapman WC, Wright K, Blair TK, CW Pinson. Clinical experience with cryosurgery for advanced 
hepatobiliary tumors. J Surg Res 1998; 75: 103-8.
20. Rubinsky B, Lee CY, Bastacky J, Onik G. The process of freezing and the mechanism of damage during hepatic 
cryosurgery. Cryobiology 1990; 27: 85-97
21. Mascarenhas BA, Ravikumar TS. Experimental basis for hepatic cryosurgery. Sem Surg Oncol 1998; 14: 110-5.
22. Bishof J, Christov K, Rubinsky B. A morphological study of cooling rate response in normal and neoplastic 
human liver tissue: cryosurgical implications. Cryobiology 1993; 30: 482-92.
23. Mazur P. The role of intracellular freezing in the death of cells cooled at supraoptimal rates. Cryobiology 
1977; 14: 251-72.
24. Ross WB, Horton M, Bertolino P et al. Cryotherapy of liver tumours- A practical guide. HPB Surg 1995; 8: 
167-73.
25. Cuschieri A, Crosthwaite G, Shimi S, et al. Hepatic cryotherapy for liver tumors: development and clinical 
evaluation of a high-efficiency insulated multineedle probe system for open and laparoscopic use. Surg 
Endosc 1995; 9: 483-9.
26. Iannitti DA, Heniford T, Hale J, Grundfest-Broniatowski S, Gagner M. Laparoscopic cryoablation of hepatic 
metastases. Arch Surg 1998; 133: 1011-5.
Joris Joosten.indb   24 13-11-2008   15:14:56
25
Cryosurgery in the treatment of colorectal liver metastases
27. Lezoche E, Alessandro M, Paganini M et al. Ultrasound-guided laparoscopic cryoablation of hepatic tumors: 
preliminary report. World J Surg 1998; 22: 829-36.
28. Adam R, Majno P, Castaing D, Giovenardi R, Bismuth H. Treatment of irresectable liver tumours by 
percutaneous cryosurgery. Br J Surg 1998; 85: 1493-4.
29. Schüder G, Pistorius G, Schneider G, Feifel G. Preliminary experience with percutaneous cryotherapy of 
liver tumours. Br J Surg 1998; 85: 1210-1.
30. Seifert JK, Morris DL. World survey on the complications of hepatic and prostate cryotherapy. World J Surg 
1999; 23: 109-14.
31. Goodie DB, Horton MDA, Morris RW et.al. Anaesthetic experience with cryotherapy for treatment of 
hepatic malignancy. Anaesth Intens Care 1192; 20: 491-6.
32. Ruers TJM, Joosten JJA, Jager GJ, Wobbes T. Cryosurgery in the treatment of colorectal liver metastases: long 
term results. Br J Surg, in press.
33. Finlay IG, Seifert JK, Stewart GJ Morris DL. Resection with cryotherapy of colorectal hepatic metastases has 
the same survival as hepatic resection alone. Eur J Surg Oncol 2000; 26: 199-202.
34. Charnley RM, Thomas M, Morris DL. Effect of hepatic cryotherapy on serum concentrations of patients with 
multiple inoperable hepatic metastases from colorectal cancer. Aust N Z J Surg 1991; 61: 55-8.
Joris Joosten.indb   25 13-11-2008   15:14:56
Joris Joosten.indb   26 13-11-2008   15:15:00
Chapter 3
Local radiofrequency ablation techniques for liver 
metastases of colorectal cancer
Crit Rev Oncol Hematol 2007; 62: 153-63.
J Joosten 
T Ruers 
Joris Joosten.indb   27 13-11-2008   15:15:02
2
Chapter 3
Joris Joosten.indb   28 13-11-2008   15:15:03
2
Local radiofrequency ablation techniques for liver metastases of colorectal cancer
Abstract 
Local ablative techniques have been used for several decades in the treatment of colorectal liver 
metastases and are gaining more and more interest. At this time radiofrequency ablation is the 
most popular local ablative technique with interesting results on local tumour control, disease free 
and overall survival. However, the exact place in the treatment of non-resectable colorectal liver 
metastases and its possible place in the treatment of resectable liver metastases has still to be 
defined. 
This article describes the feasibility, advantages and disadvantages of radiofrequency ablation, 
together with the results of the most cited articles, to form a critical review on the use of this 
technique in the treatment of colorectal liver metastases.
Introduction
Surgical resection is still considered the gold standard for the treatment of colorectal liver metastases. 
However, only a selected group of patients is amendable for resection. Major contraindications for 
resection are multifocal bilobar disease or metastases close to major vascular or biliar structures. In 
these cases radical surgical treatment may lead to insufficient hepatic reserve after resection. 
Several local tumour ablative techniques may offer an alternative therapeutic option in case of non-
resectable liver metastases. In the past cryosurgery has proven to be a relatively safe and effective 
ablative technique 1-3. Less common used techniques with variable results in different series are 
percutaneous ethanol injection (PEI), transarterial chemoembolization (TACE) and laser induced 
thermotherapy (LITT) 4-6. Among all local ablative techniques, radiofrequency ablation (RFA) is the 
most widely used technique. The technique itself is easy to perform and morbidity is low 7-21. 
Liver tumours of all origin can be treated by RFA. Where the technique has shown to be effective in 
hepatocellular carcinoma and neuroendocrine tumours, its efficacy in patients with colorectal liver 
metastases is still debatable 22,23. This article presents an overview of the technique of RFA and the 
results obtained thus far in patients with colorectal liver metastases. 
Principles of thermal ablation
The use of heat for local tissue ablation is a principle already described in ancient Greek papers. It 
was Jaques-Arsene dÁrsonval in 1891, who was the first to describe increasing tissue temperatures 
by passing high current through living tissues. Radiofrequency current in tumour treatment was first 
described around 1910 when Beer and Clark treated bladder, breast and skin cancers 24. The basic idea 
behind local tumour ablation is to selectively destruct tumour tissue (including a rim of normal tissue 
around the tumour) without significant damage to vascular structures in the remaining liver and 
hence consequent loss of large areas of normal liver tissue.
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During RFA a small electrode is placed within the tumour, enabling the delivery of radiofrequency 
energy directly to the tissue. Radiofrequency current generates ionic agitation, which is converted into 
frictional heat. Tissue damage already occurs at temperatures above 42°C. Above 60°C denaturation 
of cellular proteins starts and cell damage is irreversible. It is remarkable to notice that RFA specimens 
that were resected directly after the heating process showed no evident coagulation necrosis where 
as specimens treated in the same manner, but resected after 3-7 days, contained evident necrosis 25. 
Only special stainings on mitochondrial activity and LDH-ase activity were able to identify cellular 
destruction immediately after RFA. 
Initially the technique was limited by insufficient heat production as the energy delivered from the 
electrode tip decreases in proportion to the square of the distance to the electrode. Moreover, 
tissues around the electrode tip show a tendency to desiccation and charring, resulting in an 
increased impedance and therefore decreased current, and hence a limited zone of adequately 
heated and destroyed tissue. One way to overcome this problem has been cooling of the electrodes. 
By running saline through the RFA needle the diameter of effectively coagulated tissue is significantly 
increased (Tyco Healthcare, USA / Celon Medical Systems, Teltow, Germany). Another feature that 
has increased the area of necrosis is the introduction of expandable electrodes. These multiprobe 
array needles are introduced collapsed within a hollow needle (14-15G). Once positioned within the 
tumour multiple prongs are deployed resulting in a final umbrella-like configuration (RITA Medical 
systems, California, USA and Radiotherapeutics, California, USA.). Initially these devices were able to 
induce tissue necrosis up to 4 cm, with more recent devices a diameter up to 6 cm of tissue necrosis 
can be obtained. 
At the moment there is a great variety in RFA electrodes and electrode systems. In general plain, 
cooled, expandable, wet and bipolar electrodes can be recognized. Also there are electrode designs 
using double combinations like cooled-wet or expandable-wet electrodes. Even triple combination 
electrodes are on the market. Electrode systems can be used with one or multiple electrodes and also 
the electric mode in which they are used is variable. In the monopolar mode all electrodes have the 
same polarity and current flows in the same direction to the grounding pad. Using bipolar electrode 
systems, the current flows between two ore more parallel inserted electrodes.
A major problem when comparing different reports on RFA is the lack of uniformity and incomplicity 
in which the used RFA techniques are described. Evidently there was strong need for standardization 
of terminology and reporting criteria, as were recently provided by the International Working Party 
on Image-guided Tumour Ablation 26. Also, Mulier et al analysed the performance of several probes 
and electrode systems and provided a logical, unequivocal terminology to describe RFA electrodes 
and systems 27. Besides they analysed the performance of several probes and concluded that the 
size and geometry of the hepatic lesions induced by the different devices was still quite variable. 
Moreover, with normal blood flow, the diameter of the lesions was often smaller than suggested and 
lesions were rarely perfect spheres but either ellipses or flattened spheres. Distortion of RFA lesions 
nearby vessels was common but could partially be prevented by blood flow occlusion. From their data 
it can be stated that physicians should be well familiar with the accurate size and geometry of the RFA 
lesions in order to perform optimal tumour destruction.
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It has to be stated that with the (ongoing) developments in radiofrequency equipment and gaining 
experience in treatment of liver metastases, data from the early days of RFA are less convincing then 
recent results, which show much better total tumour ablation, less local recurrence and greater 
ablation zones even at difficult anatomic sites. In interpreting literature on the efficacy of RFA, these 
developments into time should be taken into concern. Moreover, it should be noted that the efficacy 
of RFA ablation is strongly related to the imaging technique during the ablation process. For example, 
MRI and CT offer considerable better monitoring capabilities than ultrasound 28. Hence, results of e.g. 
percutaneous RFA can be expected to be best when performed under MRI or CT guidance.  
Technique and approach of radiofrequency ablation
Before RFA is considered, patients should be staged by contrast CT of the chest and abdomen in order 
to visualise the number and location of all liver lesions and to judge the presence of extrahepatic 
disease. With regard to the detection of extrahepatic disease, functional imaging by FDG-PET should 
be considered as an essential adjunct to conventional CT. Once the number, the size and precise 
position of the metastases in relation to large vessels and bile ducts is determined, the role of RFA 
for the treatment of the metastases can be determined. Radiofrequency ablation can be performed 
in several ways: percutaneously, laparoscopically and by laparotomy. Generally the approach used is 
dependent on the profession of the clinician. Initially radiofrequency ablation was almost exclusively 
positioned within the field of radiology. Due to the small diameter (14 -17 gauge) of the electrodes the 
technique proofed to be well suited for percutaneous treatment of liver lesions. Later on surgeons 
started to use RFA in order to increase the number of patients who might benefit from resection. In 
these cases RFA was used in addition to resection in order to treat non-resectable lesions that are 
left over after resection of the main tumour mass. In general, however, the percutaneous technique 
is still the most common used approach world wide 29,30.
The open and laparoscopic approach may have several advantages. First, during the open approach, 
RFA of non-resectable lesions can be performed in combination with resection of lesions that can not 
be treated effectively by RFA because of their large size. Second, laparotomy or laparoscopy allows 
thorough evaluation of the extent of liver involvement by inspection and intraoperative ultrasound. 
Third, during open and laparoscopic RFA adjacent organs can easily be protected from burn injuries. 
The advantages of percutaneous techniques are obvious: less surgical trauma, shorter hospital stay 
and lower costs. It is also easier to repeat percutaneous treatment in case of residual tumour or 
recurrence. The main disadvantage of percutaneous treatment seems that it is less reliable, especially 
for larger lesions and superficial lesions. 
For all approaches, correct positioning of the RFA probe is crucial which requires experienced 
skills. For example, Poon et al describe a clear learning curve for RFA percutaneously as well as 
surgically 31. In their first 50 patients complete tumour ablation was achieved in 85% (most incomplete 
ablations in percutaneously treated patients) where the next 50 patients 100% tumour ablation was 
accomplished.
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Percutaneous approach
The percutaneous approach is least invasive, carries a low morbidity, is cost effective and can be 
performed as outpatient procedure under conscious sedation or general anaesthesia dependent on 
the extent of disease. Among others, the technique may especially be applicable in patients with 
major comorbidity not suited for surgical treatment. On-line monitoring of the ablative procedure is 
crucial in order to obtain complete tumour destruction. Monitoring can be performed by ultrasound, 
CT scanning or even by MRI. During RFA a hyperechoic area is formed around the tip of the electrode 
due to the formation of bubbles from evaporated water. Ultrasonography, however, provides only 
a rough estimate of the size of the ablation since the boundaries of this hyperechoic area do not 
automatically correlate with the coagulative damage. Moreover, ultrasound visualisation of the 
destruction process is often hampered by gas bubbles that develop during vaporisation. These gas 
bubbles can persist for more than 20 minutes after the end of the procedure, which often limits the 
optimal visualization of the destruction area. Both CT and MRI imaging have been reported to be more 
reliable in this regard. After thermal treatment, CT shows a round or teardrop shaped hypo attenuated 
area which is sharply demarcated from normal liver tissue and which allows accurate monitoring 
of the treatment effect. Also MRI allows accurate monitoring of the treatment effects 32. Selected 
sequences during MRI can monitor temperature elevations in the tumour and surrounding tissue 
which results in increased treatment efficacy. Nevertheless, for the percutaneous approach of thermal 
ablation, ultrasonography is still the most common method used, mainly because of its availability, 
speed, and low cost. Moreover, recent developments using contrast enhanced ultrasonography may 
overcome part of the shortcomings of conventional ultrasound and seem promising in monitoring 
the RFA process 33. However, even contrast enhanced ultrasound is not as sensitive for interventional 
imaging as state of the art CT or MRI 28. Therefore, the results of percutaneous ultrasound guided 
RFA ablation can be expected to be worse when compared with CT or MRI guided RFA. Detailed 
information on the relation between imaging modalities and treatment results of percutaneous RFA 
is, however, limited.  
Laparoscopic approach
The laparoscopic approach, is like the percutaneous technique, minimal invasive, allows fast recovery 
and shows minimal morbidity. Although laparoscopic RFA is performed under general anaesthesia, 
usually patients can leave the hospital the same day or the morning after surgery. Compared to the 
percutaneous technique, laparoscopic RFA allows intraoperative staging, both using the videoscope 
and laparoscopic ultrasound. Amongst others, Rahusen et al show that by laparoscopy and laparoscopic 
ultrasound, additional hepatic metastases could be identified in up to 17% of the patients 34. Moreover, 
the laparoscopic approach is advantageous for superficial lesions and for lesions adherent to structures 
that can be damaged by thermal ablation such as colon and stomach. In addition laparoscopic RFA 
may be performed together with the laparoscopic colorectal procedure for the primary tumour. As 
indicated by Berber et al, RFA can be safely used concomitant with colon resections. Recovery of 
either procedure is not impaired by the other 35.
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Laparoscopic RFA certainly requires certain skills by the surgeon both for performing RFA as well 
as monitoring the procedure by laparoscopic ultrasound, but in experienced hands mobilization of 
the liver and vascular inflow occlusion can be performed as in open surgery. Combined laparoscopic 
procedures, such as resection and RFA, are still experimental. Croce et al. describe their experiences 
with laparoscopic liver resection, with or without additional RFA 36. They addressed the feasibility of 
this approach and suggested wider acceptance for this technique with the development of better 
laparoscopic tools and ongoing laparoscopic training and experience. 
Open procedure
Laparotomy is still the method preferred in case of grossly resectable disease with a few non-resectable 
lesions 7,8,10,11,13,14,16-18. Moreover, intra-operative ultrasound can be best performed in an open procedure 
and the liver can be fully mobilised allowing optimal conditions for adequate placement of the RFA 
probes. Liver mobilisation may especially, be advantageous for those lesions situated at the dome of 
the liver, although in experienced hands these regions can also be reached during the percutaneous 
or laproscopic approach. Furthermore, during open surgery, clamping of the blood flow to the liver 
may reduce the heat sink effect, allowing more effective tumour necrosis in tumour situated close to 
large vessels. Prolonged clamping may, however, lead to venous trombosis and biliary strictures. 
Postoperative follow up imaging
After local ablative treatment, contrast enhanced CT scan is generally used for follow up. The sharp 
hypoattenuated areas seen immediate after treatment usually decrease in size in the months after 
treatment. By 3 to 6 months, there may be a marked regression of the necrotic area, although 
treatment effects may remain visible long after this time. In case of tumour recurrence a faint, irregular, 
hypoattenuated area becomes visible around the margins of the ablated tissue that increases in size 
on follow up scans. With MRI comparable images are obtained 37. 
More recently FDG-PET scan has been used to follow up local ablative treatment. After successful 
treatment metastatic lesions become photopenic. Persistent activity after local tumour treatment 
is highly suspicious for inadequate treatment. Moreover, the reappearance of activity in photopenic 
areas is strongly indicative for tumour recurrence 38-42. 
Complications
In a group of 608 patients Curley et al described early and late complications of RFA 43. They show 
an early complication rate of 8.6% in open RFA versus 4.4% in percutaneously performed RFA. Late 
complications (developing more then 30 days after RFA) arose in 2.4% of patients with no difference 
between percutaneously and surgically treated patients. Livraghi et al reported in a multicentre 
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survey on the complications of percutaneous RFA. In total 2320 patients with 3554 lesions, both 
hepatocellular carcinoma and metastases, were treated according to a standardized protocol 29. Six 
deaths occurred (0,3%) while 2,2% of the patients showed major complications such as haemorrhage, 
intestinal perforation, abscess formation and neoplastic seeding. The complication rate was mainly 
related to the number of RFA sessions performed and no evident correlation was found between 
tumour size or RFA equipment used.
Giorgio et al describe complications after percutaneous RFA in 336 patients treated in a single center 
44. Major complications, including death occurred in three patients. Interesting are the figures on 
fever lasting for 1-3 days, 42%, and pain lasting for 24 hrs, 63%.
Mulier et al report in an extensive review on the complication rate in 3670 patients, treated for a 
variety of liver tumours by RFA either percutaneously, laparoscopically or during laparotomy 30. The 
complication rates were 7.2%, 9.5% and 9.9% respectively. The mortality rate during percutaneous RFA 
was 0.5% and zero for both other approaches. 
Most encountered complications were: intra-abdominal bleeding (1.6%), abdominal infection (1.1%) 
and biliary tract damage (1.0%). Other complications that occurred less frequently were pulmonary 
related complications, dispersive pad skin burns, liver failure, visceral damage, and hepatic vascular 
damage. When RFA was combined with resection, mortality and morbidity rates were comparable 
to patients treated by resection alone, 4.5% and 31.8%, respectively. They conclude that although the 
complication rate after RFA is low, it is higher then assumed and many complications can prevented.
Several risk factors for complications have been identified. For example subcapsular tumours carry 
a higher risk of abdominal bleeding especially during the percutaneous and laparoscopic approach. 
These bleedings are generally self limiting, especially for lesions deep in the liver, and transfusion 
is not required. Careful cauterisation of the electrode track can prevent this complication. Thermal 
damage of neighbouring organs was mostly found in the percutaneous approach. For this reason 
an open or laparoscopic approach is advised for subcapsular tumours within 2 cm of adjacent 
viscera, although recently the injection of gas or fluids has been described as a new technique to 
prevent thermal injury during the percutaneous approach. Biliary tract damage exclusively occurs 
in central tumours. Tumours located within 1 cm of the main biliary ducts are generally considered a 
contraindication to RFA. 
The risk of electrode seeding is limited to the percutaneous approach and is generally assumed 
between 0.2 and 2.8%. One group describes a rate of 12.5%. Careful cauterisation of the electrode 
track should be performed to prevent this complication. RFA of subcapsular tumours carries a higher 
risk of track seeding than deeper situated tumours. For this reason subcapsular tumours should not 
be approached by a perpendicular route during the percutaneous approach. For these tumours, a 
laparoscopic approach or open approach is often even a better choice.
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Local recurrence
The first major studies on radiofrequency ablation for colorectal metastases were presented by Curley 
and Pearson et al 7,8. Curley describes the results in 123 patients treated either percutaneously (35%) 
or by laparotomy (75%). Median diameter of the lesions treated was 3.4 cm. Local recurrence was 1.8 
and 2.4 percent on lesion and patient base respectively. The same recurrence rates were described 
by Pearson, with a median diameter of the lesions in this series of 3.8 cm. In this latter study also a 
comparison was made between RFA and cryosurgical ablation: results were in favour of RFA with a 
lower local recurrence rate and less morbidity. With gaining popularity of RFA several studies have 
followed with variable results on local recurrence rate varying from 2%- 60% 7,16,45. Table 1 shows the 
local recurrence rates and treatment characteristics of the major studies on RFA. A meta-analysis on 
the local recurrence rate after hepatic RFA was recently published by Mulier et al 46. Amongst others, 
this series comprised hepatocellular carcinoma (2369 lesions), unspecified lesions (1046) and colon 
cancer metastases (763 lesions). In a multivariate analysis, significantly less local recurrences were 
observed for small size lesions (P < 0.001) and for lesions treated by a surgical (versus percutaneous) 
approach (P < 0.001). Moreover, lesions close to vascular structures or located subcapsular showed a 
higher tendency for recurrence. Except for neuroendocrine tumours that showed a more favourable 
local recurrence rate, histology of the lesions was of less importance. 
In an earlier analysis the same authors describe 806 patients with colorectal liver metastases treated 
by RFA 47. For tumours < 3 cm, local recurrence rate after open or laparoscopic approach was zero 
versus 19% for the percutaneous approach. For lesions > 3 cm, the local recurrence rate after the 
open or laparoscopic approach was 20% versus 51% for the percutaneous approach. Also Bleicher 
et al. showed that tumour size was the most important prognostic indicator for local recurrence 17. 
For large lesions, multiple probes insertions are necessary to obtain a treatment zone large enough 
to include all tumour tissue. It seems that the efficacy of these overlapping treatment zones is still 
unreliable, resulting in high local recurrence rates. From all these data it can be concluded that open 
and laparoscopic RFA proves to be effective for tumours up to 3 cm, with a definite tumour control up 
to 90%. For lesions larger than 3 cm local recurrence rates are still high and are reported over 20%. 
Moreover, the different series show that laparoscopic RFA and RFA performed during open surgery 
is more reliable than percutaneous RFA. In a direct comparison of techniques, Bleicher et al showed 
that the laparoscopic route and the open route by laparotomy were not significantly different with 
regard to local recurrence rate (6.7% and 9.0% respectively), while during the percutaneous approach 
the local recurrence rate was significantly higher (15.1%) 17. During the open and laparoscopic approach 
the surgeon has the opportunity to reduce the heat sink effect by the large vessels by clamping the 
portal ligament. Furthermore superficial lesions as well as lesions in the dome of the liver are more 
easily accessible by these approaches compared to the percutaneous approach. These data, as well as 
the results from the multivariate analysis as performed by Mulier et al., should however be interpreted 
with care, since the imaging technique used during percutanous RFA seems crucial with regard to the 
results. Excellent mono-institutional series on percutaneous RFA have been published using CT or 
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MRI guided RFA ablation. These shortcomings of currently published data on RFA are generally not 
taken into account when reporting overall results on percutanous RFA. A clearly differentiated view 
on the results of percutanous RFA seems therefore appropriate. 
Table 1  Results of RFA for colorectal liver metastases.
Patients
Lesions Approach
Size of 
lesions (mm)
No of lesions 
per patient 
Local recurrence 
total
Colorectal	
metastases
Patient	
based
Lesion	
based
Curley
1999	[4]
 123  61  169 open/ perc 5-120
34 median
1-5 2% 2%
Pearson
1999	[5]
 92  46  138 open 5-120
38 median
1-5 3% 2%
De	Baere
2000	[6]
 68  58  121 open/perc 5-42
21 mean
1.6 median 16% 9%
Wood
2000	[7]
 84  37  231 open/ perc/ lap 3-90
30 median
2.5 median 18% 7%
Bilchik
2000	[8]
 68  30  181 open/ perc/ lap 5-90
20 median
1-13
2 median
7% 3%
Solbiati	
2001	[9]
 117  117  179 perc 6-96
28 median
1-4 ns 39%
Bowles
2001	[10]
 76  39  328 open/ perc/ lap 4-180
30 median
3.3 median 26% 9%
Machi
2001	[11]
 46  25  204 open/ perc/ lap 5-180
36 mean
1-14 ns 9%
Adam
2002	[12]
 33  ns  43 perc 28 median 1-4
1.32 median
16% 18%
Pawlik
2003	[13]
 172  124  737 open 3-120
18 median
1-12
1 median
8% 2%
Bleicher
2003	[14]
 153  59  447 open/ perc/ lap 5-135
25 mean
1-13
2.0 median
21% 11.6%
Abdalla
2004	(rfa	only)	[15]
 57  57  110 open 25 median 1-8
1 median
9% ns
Gillams
2004	[16]
 167  167  684 perc 10-120
39 mean
1-27
4.1 median
14% ns
Berber
2005	[17]
 135  135  432 lap 12-102
38 median
1-12
2 median
46% ns
Navarra
2005	[18]
 33  23  297 open/lap 10-200 1-20
5.2 median
17% ns
Local recurrence rate related to size of RFA lesions and approach of RFA. ns: not stated, Perc: percutaneous, Lap: laparoscopic. In this table several 
studies on the treatment of colorectal metastases are listed. In most papers also treatment of other hepatic malignancies is described. The number 
of treated colorectal metastases is mentioned separately.
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Results for resectable lesions
Thus far, it can be concluded that the use of radiofrequency for the treatment of colorectal liver 
metastases is safe and feasible. However, two crucial questions have still to be addressed. First, is 
tumour destruction by radiofrequency equal in curability to surgical resection of resectable colorectal 
liver metastases and second, what is the effect of RFA on survival, in addition to chemotherapy, in 
patients with non-resectable colorectal liver metastases 48. With regard to the first question hardly 
any data are available. A randomised trial in France has failed due to lack of recruiting patients. Only 
indirect data from retrospective or observational studies can give an ambiguous impression. In a 
retrospective study by Oshowo et al, 45 patients with solitary liver metastases were identified that 
had been treated by resection or RFA 49. Liver resection was performed in 20 patients, in the remaining 
25 RFA ablation was performed because resection was contra-indicated for the following reasons; 
lesion close to major vessels, high co-morbidity, or stable extrahepatic disease. Although RFA was 
applied to a wider spectrum of patients, e.g. also to nine patients with extra-hepatic disease, survival 
in both groups was comparable. Median survival after liver resection was 41 months with a 3 year 
overall survival rate of 55.4 %. In the RFA group these figures were 37 months and 52.6% respectively. 
These results are in strong contradiction to results published by Abdalla et al 18. In their series RFA plus 
resection or RFA only for “non-resectable” patients was compared with the gold standard of resection. 
The only detectable difference between the groups was in the anatomic distribution of tumours, 
which made complete resection impossible in the RFA groups. The authors stated that there were 
no differences between the groups either in tumour size, number of lesions, or patient and primary 
tumour characteristics. Despite comparable characteristics of traditional predictors, resection 
resulted in significant better overall survival. Four year survival after resection (n= 190), RFA plus 
resection (n = 101) and RFA only ( n = 57) was 65%, 36% and 22% respectively. Sub-analysis for patients 
with solitary lesions showed similar results. Survival differences appeared to be associated with a 
significant higher intrahepatic failure rate and a higher true local recurrence rate after RFA. Overall 
intrahepatic recurrence after resection, RFA plus resection and RFA only were 11%, 28% and 44% 
respectively. These results are, however, difficult to understand, with identical patient and tumour 
characteristics in all three different groups. 
Theoretically, at least for small liver metastases (< 3 cm), RFA should achieve equal results to resection. 
As in such cases local recurrence after RFA is extremely low and disease recurrence elsewhere should 
be identical whether lesions are treated by RFA or resection. Indeed, a prospective case control 
study in patients with colorectal liver metastases treated locally by cryotherapy or resection, showed 
a comparable overall survival between both treatment modalities, even in spite off a higher local 
recurrence rate after cryotherapy 50. 
At present, however, reliable data on the results of RFA in patients with resectable colorectal liver 
metastases are lacking and at this stage RFA should not be considered equivalent to hepatic resection. 
It may well be, however, that RFA may start to replace resection in those patients in whom laparotomy 
and resection is hazardous, e.g. patients with a small liver recurrence after earlier hepatectomy. Elias et 
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al, describe 47 patients with local recurrence after hepatectomy for malignant tumours (29 colorectal 
tumours) that were treated with percutaneous RFA instead of resection 51. Overall survival at 1 and 
2 years was 88% and 55% respectively. In a matched historical control group treated by resection 
these figures were 84% and 60% respectively. Although such non-randomised data clearly point into 
the direction of less invasive treatment, only randomised clinical trials can determine whether RFA 
ablation can achieve an equivalent survival rate compared to resection. 
Results in patients with non-resectable liver metastases
As with many new developments, RFA has mainly been used in patients with more advanced disease 
in which curative treatment by resection was judged not feasible. However, in this group of patients, 
interpretation of the results of RFA on overall survival is extremely difficult. First, many publications 
do not refer to a single histological tumour type, but vary from primary malignant tumours to 
different metastatic tumours or even benign lesions. Second, in many studies RFA is combined with 
other treatment modalities such as resection, systemic chemotherapy or intra-arterial chemotherapy. 
Most importantly, studies generally use different patient selection criteria which makes comparison 
of results difficult. For example, the median number of lesions treated by RFA varies considerably 
between the different studies. In several studies one might even wonder why patients were treated 
by RFA and were not considered for hepatic resection. Taken together, there are concerns about 
taking the results of the studies so far at face value. 
In general, one year overall survival after radiofrequency of non-resectable colorectal liver metastases 
varies generally between 80% and 93%, 2 year overall survival is reported between 50% and 75%, 
while 3 year overall survival varies between 21%and 53% (Table 2). In the patient populations selected 
in the different studies the number and diameter of lesions is generally low. In most studies the mean 
number of metastases is less than 2, while most lesions treated are smaller than 3 cm. Between the 
studies, however, there are significant differences between these figures, which indeed may reflect 
differences in resectability criteria. The way radiofrequency was applied also varies considerably. Most 
series include the open approach as well as the percutaneous or laparoscopic approach. Although 
local recurrence seems higher during the percutaneous approach, comparison of the different 
series does not allow any conclusions on the preferred technique with respect to overall survival. 
Apart from the approach, several tumour specific characteristics may determine definite outcome. 
In a prospective study by Berber et al. several predictors of survival were analyzed in 135 patients 
that underwent laparoscopic RFA 20. Median survival in this series was 28.9 months. Patients with a 
carcinoembryonic antigen (CEA) level of less than 200 ng/ml showed an improved survival compared 
with those measuring a CEA of more than 200 ng/ml (34 vs 16 months). Apart from the CEA level the 
size and number of lesions proved to be of importance. Patients with the dominant lesion less than 
3 cm in diameter had a median survival of 38 months versus 34 months and 21 months for patients 
with lesions between 3 and 5 cm and lesions greater than 5 cm, respectively. Survival in patients with 
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one to three tumours was superior to survival in patients with three or more tumours (29 months vs 
22 months). Also others observed that the number of lesions and the ability for complete ablation, 
which is directly related to size, are independent prognostic factors for survival 16,19,21.   
As for hepatic resection, there are hardly any data on the maximum number of lesions for which 
RFA results in a beneficial effect on survival. In the study by Navarra et al, patients with more than 
7 lesions showed a median overall survival of less than 20 month, while Gillams et al. showed that 
patients with more than 10 lesions had a median survival after RFA of only 16 months 19,21. These results 
are in concordance with Pawlik et al, who showed that RFA in patients with 10 or more lesions resulted 
in only a marginal period of disease free survival (2.3 months) 16. From these studies it appears that 
with an increasing tumour load the beneficial effect of local tumour control by RFA is fading. The 
same holds true for patients in which complete local tumour ablation cannot be obtained. Navarra et 
al. showed that patients with incomplete ablation did not benefit from the procedure, which makes 
that, at present, RFA for lesions above 5 cm is questionable 21. In patients with non-resectable disease 
that consists of a combination of lesions that are smaller as well as larger than 5 cm, resection should 
still be the preferred method for the treatment of lesions larger than 5 cm, while RFA should be 
reserved for the treatment of the smaller non-resectable deposits. Recently, Elias et al reported on 
a new approach called post radiofrequency trans-metastasis hepatectomy 52. In case of multiple liver 
metastases with also tumour in the plane of the preferred resection, RFA is performed on these 
lesions and afterwards resection is performed through this zone of ablated tissue. They show this can 
be done safely and can be curative in a selective group of patients.
In patients with extrahepatic metastases, RFA of liver lesions is generally contra-indicated. However, 
in the series by Berber et al, the presence of extahepatic disease did not affect survival 20. In this 
series, patients with extrahepatic disease undergoing RFA for liver metastases showed a median 
overall survival of 2.4 years versus 2.0 years in patients without extrahepatic disease. This finding 
is difficult to understand since it is well known that patients with liver only disease undergoing 
resection do better than those with extrahepatic disease. The authors suggest that in patients with 
more advanced liver disease, untreated extrahepatic disease is a less important prognostic factor 
compared to patients in which hepatic resection can be performed. However, most other studies do 
not find a beneficial effect of RFA in patients with extrahepatic disease. For example in the series by 
Gillams et al, RFA in the presence of extrahepatic disease resulted in a median overall survival of 15 
months compared to 31 months in patients without extrahepatic disease 19. 
So, from the results thus far it can be concluded that, like in the series of hepatic resection, the amount 
of tumour burden in the liver, as suggested by the size and number of metastases and the CEA level, 
determines overall survival after RFA. As with resection, RFA for non-resectable lesions does only 
seem to be beneficial when all lesions within the liver can be treated adequately in the absence of 
extrahepatic disease. 
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Disease free survival 
Disease free survival in all series varies considerably (table 2). Most series, however, show a disease 
free survival of 1 year or less. Depending on the indications and the extent of liver disease at the time 
of radiofrequency ablation, disease free survival varies between 6 and 12 months. In the series of 
Bleicher et al, in which a median number of 2.0 lesions was treated 
per patient, disease free survival at median follow up (11 months) was 28% 17. Solbiati et al, who treated 
a median number of 1.5 lesions per patient, reports a disease free survival of 49% at 1 year. In this 
study RFA was generally followed by chemotherapy 12. Berber et al. observed a median disease free 
survival months of 6 months with pre-operative CEA level, lesions size and number of lesions as most 
important prognostic factor for disease recurrence 20. 
For more than 90% of the cases recurrent disease occurs outside the treated area, either within the 
liver or at extrahepatic sites. For example, Abdalla et al. observed intrahepatic recurrence anywhere 
in the liver in 44% of the patients and extrahepatic recurrence in 40% of the cases treated 18. True 
local recurrence at the ablated site was encountered only in 9% of the patients. Because of the high 
recurrence rate outside the treated area many centres favour the use of chemotherapy after RFA 
treatment. 
However, data on direct comparison of combined treatment of RFA plus chemotherapy versus RFA 
only are lacking. Only indirect data are available by comparing treatment protocols between different 
series. In table 2, the studies using additional chemotherapy are listed. Most series, however, do not 
report whether additional post RFA chemotherapy was applied. Only six studies clearly state the 
standard use of chemotherapy after RFA 12,13,15,19-21. Adam et al. describe a disease free survival with 
standard chemotherapy after local tumour ablation of 27%, with a median follow up of 16 months 15. 
More promising figures are given by Navarra et al, reporting 75% disease free survival with a median 
follow up of 18 months 21. However, an identical range in disease free survival from 28% to 73% is 
observed in studies that do not report on the standard use of chemotherapy 7,17. Moreover, similar 
overlapping percentages are reported for overall survival between series with or without additional 
chemotherapy after RFA 16,18,19,21.  
After cryoablation, however, two series attempted to address the issue of post ablation chemotherapy 
more directly. Litvak et al. directly compared the additional effect of systemic and intrahepatic 
chemotherapy after local tumour destruction by cryoablation 53. In this study 185 patients underwent 
cryoablation with (n= 71) or without (n=114) additional systemic irinothecan and regional floxuridine. 
The median time to progression was 10 months in the ablation group only and 19 months in the 
group treated with ablation plus chemotherapy. Median overall survival was and 20 months and 30.6 
months, respectively. 
Also Preketes et al. showed a benefit on overall survival after combined treatment (cryoablation 
+ intra-arterial chemotherapy ) compared with cryoablation alone in a historical control group 54. 
Median overall survival in the combined treatment group was 19 months versus 8 months in the 
historical ablation only group. These data strongly point into the direction of standard post ablation 
chemotherapy, although randomized studies are clearly lacking. 
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Table 2 Results of RFA for colorectal liver metastases
Patients
Lesions 
Follow up  
in months 
(mean)
Overall 
survival
Disease free 
survival
Additional 
therapies
Post-RFA 
chemotherapytotal
Colorectal	
metastases
Curley
1999	[4]
 123  61  169  15 ns 73% resection ns
Pearson
1999	[5]
 92  46  138  15 ns ns resection ns
De	Baere
2000	[6]
 68  58  121  14 81% 31% resection ns
Wood
2000	[7]
 84  37  231  9 75% 43% Resection, 
CSA, HAIP
ns
Bilchik
2000	[8]
 68  30  181  12 1yr 80% 52% Resection, 
CSA
ns
Solbiati	
2001	[9]
 117  117  179  24 1yr 93%
2yr 69%
1yr 49%
2yr 35%
ns yes
Bowles
2001	[10]
 76  39  328  15 1 yr 90%
2 yr 50%
33% Resection  yes 
Machi
2001	[11]
 46  25  204  21 78% 54% Resection ns
Adam
2002	[12]
 33  ns  43  16 1yr 58% 27% Resection yes
Pawlik
2003	[13]
 172  124  737  21 2yr 75%
3yr 53%
ns Resection ns
Bleicher
2003	[14]
 153  59  447  11 60% 28% ns ns
Abdalla
2004	(rfa	only)	[15]
 57  57  110  21 3yr 37%
4yr 22%
1yr 40%
3yr 6%
ns ns
Gillams
2004	[16]
 167  167  684  17 1yr 71%
3yr 21%
5yr 14%
ns ns yes
Berber
2005	[17]
 135  135  432  ns 1yr 80%
2yr 53%
3yr 30%
ns ns yes
Navarra
2005	[18]
 33  23  297  18 1yr 73%
3yr 53%
75% HAIP yes
Overall and DFS after RFA of unresectable colorectal liver metastases in relation to additional therapies and post RFA chemotherapy. ns: not stated, 
HAIP: hepatic artery infusion pump, CSA: cryosurgery ablation. In this table several studies on the treatment of colorectal metastases are listed. In 
most papers also treatment of other hepatic malignancies is described. The number of treated colorectal metastases is mentioned separately.
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Rationale for RFA in non-resectable patients?
The rationale for RFA in patients with non-resectable colorectal liver metastases is local tumour 
control, whereas the main issue in these patients is to control systemic disease and prolong overall 
survival. These issues are often distinct and without overlap. In this regard no data from randomised 
clinical trials are available comparing RFA with the standard of care, being chemotherapy. Data on 
overall survival in these patients are limited to the reported phase II studies. Hence, the question 
whether local tumour destructive therapy by RFA has any additional benefit on overall survival over 
modern systemic chemotherapy needs still to be addressed. 
Altogether several studies on RFA for unresectable colorectal liver metastases have shown median 
overall survival times of more than 30 months. These results have been claimed to be superior to 
standard treatment by chemotherapy, which nowadays can result in a median survival of 24 months 
55. The superior results of local ablative therapy compared with chemotherapy may certainly be due to 
patient selection. Especially since patients selected for aggressive local treatment show only a limited 
number of liver metastases (most studies median number approximately 4 or less), while patients 
treated by chemotherapy may show more widespread liver involvement or even extrahepatic disease. 
Up to know, results of RFA are mainly compared with historical controls receiving chemotherapy. 
However, in order to determine the exact place of RFA in patients with non-resectable colorectal liver 
metastases, controlled clinical trials are urgently needed. Such trials should include patients with non-
resectable colorectal liver metastases, and involve a comparison between aggressive local treatment 
with RFA plus chemotherapy, versus standard chemotherapy alone. Such a trial (EORTC protocol 
40004, CLOCC, Chemotherapy plus Local ablation versus Chemotherapy) is currently ongoing. In 
this multicentre intergroup trial by the EORTC, the Arbeidsgemeinschaft für Leber Metastasen in 
Germany, and the NCRI colorectal cancer group in the UK, patients are randomly assigned to either 
oxaliplatin, fluorouracil, leucovorin and bevacizumab, or oxaliplatin, fluorouracil, leucovorin and 
bevacizumab plus RFA. Primary end point of the study is overall survival at 30 months, secondary 
end points are progression free survival and Health Related Quality of Life. This trial opened late 
2003 and so far 110 patients of the 152 have been assigned. The study allows inclusion of patients 
with unresectable liver metastases up to 10, and it has to be determined whether this large range in 
number of metastatic lesions is realistic and does not effect ultimate outcome. However, only such 
randomized trials can address properly whether RFA in patients with non-resectable disease shows 
any beneficial effect on survival. 
Conclusion
Recent literature shows that RFA for colorectal metastases is feasible and safe. Although RFA proofs 
to be effective for local tumour control, at present there is no evidence that RFA is equal to resection. 
Until such proof, resection of liver metastases remains the gold standard. The additional benefit of 
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RFA over systemic chemotherapy in patients with non-resectable colorectal liver metastases is still 
questionable and participation in randomised trials concerning this issue should be encouraged. At a 
time when purchasers of health care are looking for evidence based therapy, the need for randomised 
trials that evaluate the efficacy of RFA for non-resectable as well as resectable colorectal liver 
metastases has never been greater. Only such trials can finally define the appropriateness of RFA in 
the treatment of colorectal liver metastases.
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Summary
Background The purpose of this study was to determine the long-term efficacy of cryosurgery as an 
adjunct to hepatic resection in patients with colorectal liver metastases not amenable to resection 
alone. 
Methods Thirty patients met the following inclusion criteria: metastases confined to the liver and 
judged unresectable; the number of metastases ≤10; cryosurgery alone or in combination with hepatic 
resection allowed tumour clearance. 
Results	Median follow-up was 26 months (9-73 months). Overall 1- and 2-year survival was 76% and 61% 
respectively. The median survival was 32 months. Disease free survival at 1 year was 35%, at 2 years 7%. 
Six patients developed recurrence at the site of cryosurgery, giving the total number of cryo treated 
lesions (n=69) the local recurrence rate was 9%. 
Conclusions	In patients with colorectal liver metastases local ablative techniques can be used as an 
effective adjunct to hepatic resection to obtain tumour clearance. 
Introduction
Hepatic metastases are the main cause of death in patients with colorectal cancer 1. In patients with 
metastatic disease confined to the liver, resection offers the best chance of cure. After resection a 
5-year survival rate of 35% can be achieved 2-7. However, only a minority (10-15%) of patients with liver 
metastases is suitable for resection. Resectability is usually determined by the absence of extrahepatic 
disease, a maximum of four liver deposits and the ability to obtain free resection margins 8. Recently, 
it has been demonstrated that the presence of more than four metastases does not automatically 
preclude resectability 5,9-11 Liver resection in patients with more than four metastatic lesions has been 
shown to result in a five year survival of 25% as long as resection margins are free of tumour 5. In these 
patients with more extensive disease, however, it may be difficult to adequately resect all tumour 
tissue. It is in this group of patients that local tumour ablative techniques like cryosurgery can be 
used as an adjunct to hepatic resection 12,13. Using cryosurgery, liver deposits are frozen with the aid of 
liquid nitrogen circulating through a probe which is placed in the centre of the tumour 14. The method 
has been shown safe and to allow treatment of one or more liver metastases 12,13,15-24.
The aim of this study was to describe the long term results of cryosurgery when used either alone or 
in combination with liver resection in patients with colorectal liver metastases. 
Patients and Methods
Patient selection
Patients with documented colorectal liver metastases who met the following criteria were considered 
for cryosurgery: metastases confined to the liver; metastases judged unresectable due to technical 
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considerations related to location or extent of the disease; less than 50% of liver volume affected and 
the number of metastatic deposits was no more than 10; cryosurgery alone or in combination with 
resection would allow complete tumour eradication. 
Previous chemotherapy was not considered an exclusion criterion. To determine the extent of the 
disease prior to surgery all patients underwent spiral abdominal CT scan, chest X-ray or CT thorax, and 
more recently FDG-PET. Barium enema or colonoscopy was performed to exclude local recurrence. 
Liver function tests and CEA were evaluated routinely. 
Operative procedure 
The operation was performed as a separate procedure through an extended right subcostal incision. 
The abdominal cavity was explored thoroughly to exclude extrahepatic disease. Suspicious lymph 
nodes or peritoneal deposits were subject to biopsy and fresh frozen section. The extent of liver 
involvement was mapped out by careful palpation and intra-operative ultrasound. The number 
of lesions with their relationships to major biliary and vascular structures was determined and 
resectability assessed. Tumour size or loco-regional invasion of perihepatic structures were not 
considered a contraindication to operation as long as resection could clear all tumour tissue. In all 
cases surgical resection was considered the treatment of choice. When complete resection could 
not be achieved patients were included in the study and the decision was taken either to perform 
cryosurgery alone or to combine resection of resectable lesions with cryosurgery of unresectable 
deposits. 
Technique of hepatic cryosurgery
After localisation of the liver metastases the cryoprobe was introduced under ultrasound guidance 
into the centre of the tumour. Cryosurgery was performed as described earlier using a LCS 2000 
apparatus (Candela Corporation, Eindhoven, The Netherlands) 12,23. During the freezing process 
continuous ultrasound monitoring of the lesion was carried out to assure that the “ice ball”, visible 
as a hypo-echogenic area around the tip of the cryoprobe, exceeded the diameter of the lesion by 
about 1 cm. The volume of tumour that can be frozen with one cryoprobe depends on the diameter of 
the probe. Cryoprobes with a diameter of 5 mm and 10 mm generally result in an ice ball of 4 cm and 
6 cm respectively. By introducing more than one probe an adequately frozen area with a diameter of 
10 cm can be reached. The time of freezing was dependent on production of an adequate ice ball but 
generally one freeze period lasted for 20 minutes, followed by thawing for at least 10 minutes. Two 
freeze-thaw cycles were always performed per lesion. 
Postoperative follow-up
Postoperative follow-up was obtained at 6 weeks and then every 3 months by assessment of CEA 
and abdominal spiral CT. The first postoperative CT scan was used as a reference to evaluate liver 
recurrence. When indicated additional investigations were performed to detect recurrence outside 
the liver. Regular follow-up was reduced to twice yearly after 2 years. When new liver deposits 
became evident subsequent resection or cryosurgery was performed whenever possible. In case of 
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doubt about recurrence at the site of cryosurgery, an ultrasound guided biopsy was performed. After 
cryosurgery patients did not receive routinely chemotherapy. Chemotherapy was only started in cases 
of recurrence not amenable to resection or cryoablation.
Results
Patient and treatment characteristics
Between January 1994 and October 1999, 30 patients with unresectable liver metastases from 
colorectal cancer met the prospective criteria and underwent hepatic cryosurgery with or without 
additional hepatic resection. These patients represented 15% of the cases surgically treated for 
colorectal liver metastases within the study period. Sixteen patients had synchronous metastases, 
14 had metachronous metastases (Table 1). The median time from detection of liver metastases to 
surgery was 5.5 months. In 7 patients this period was more than one year caused by delay in primary 
referral. Eleven of the 30 patients were initially treated by chemotherapy before referred. By that 
time 8 patients showed progression of the disease noted by enlargement of the liver deposits on CT 
scan. In these patients the median duration of chemotherapy was 10.5 months. Another 8 patients 
developed metastases during adjuvant chemotherapy. Thus a total of 16 patients had metastases that 
were progressive on chemotherapy at the time of surgery. 
Table 1  Patient characteristics
Number of patients 30
Sex ratio (M : F) 19 : 11
Mean (range) age (years) 62  (45-79)
Synchronous/metachronous 16/14
Median (range ) interval from diagnosis of primary tumour to detection of metachronous 
metastases (months)
12.5  (7-29)
Median (range) time from detection of metastases to cryosurgery (months) 5.5  (1-41)
Failure chemotherapy prior to cryosurgery 16  (53%)
Median (range) follow-up (months) 26  (9-73)
The number of liver metastases per patient varied from 1 to 10 with a median of three. The number 
of nodules per patient treated by cryosurgery ranged from 1-7, with a median of two. The tumour 
and treatment characteristics of all patients are given in Table 2. Fourteen patients had four or more 
lesions, 16 patients had less than four metastases. Seven patients were treated by cryosurgery alone. 
In all other cases cryosurgery was combined with resection of the resectable lesions. Out of 115 
metastases, 69 (60%) were treated by cryosurgery.
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The size of the metastases varied from 1 to 18 cm, with a maximum diameter of the cryo treated 
lesions of 9 cm. Most lesions treated by cryosurgery were < 4cm. 
Three patients underwent repeat cryosurgery for recurrent liver metastases. One patient was treated 
twice for recurrence, thus the total number of cryosurgical procedures was 34. The median follow-up 
after cryosurgery was 26 months. The median follow-up after detection of metastases was 40 months. 
Table 2  Tumour and treatment characteristics
Number of metastases Size metastases
Size cryo-treated 
metastases
<4 ≥4 <4 cm ≥4 cm <4 cm ≥4 cm
Number of patients 16 14  9  21*
Patients treated by cryosurgery 
only
 4   3  1  6
Patients treated by cryosurgery 
plus resection
12 11  8  15
Number	of	lesions	treated  82  33# 47 22
* Number of patients according to the size of the largest metastatic lesion.# Number of lesions according to size.
Mortality and morbidity
There was one postoperative death from acute myocardial infarction 14 days after an uncomplicated 
cryosurgical procedure. The morbidity rate in the 34 procedures was 26%. Haemorrhage from a cryo 
treated lesion was encountered twice. One patient had to be returned to the operating room because 
of haemorrhage, another patient required packing of the liver during the procedure due to hepatic 
cracking of the ice ball with associated haemorrhage. Four patients developed an abscess of the cryo 
treated area. All were treated by percutaneous drainage. Three patients developed pneumonia after 
the procedure. Right pleural effusion was observed in most patients probably due to the irritative 
process beneath the diaphragm. Total operating time varied from 2 hours to 6 hours. The median 
hospital stay for the 34 procedures was 10 days (5-106 days). 
Survival
At a median follow-up of 26 months, 14 patients had died, 13 due to metastatic disease and one 
postoperative death. After cryosurgery the overall survival at 12 months was 76% and at 24 months 
was 61% (Figure 1). Median survival was 32 months (range 0.5-58). One and 2-year survival after 
detection of the metastases was 83% and 68% respectively. Median survival after detection of the 
metastases was 46 months. Patients with lesions smaller than 4 cm had an increased survival as 
compared to those with lesions ≥4 cm (Figure 2). Median survival for patients with lesions < 4 cm 
was 46 months compared with 18 months for patients with lesions ≥4 cm (P < 0.05, Log-Rank). No 
significant correlation was found between the number of metastases and survival. 
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Figure 1  Kaplan-Meier curve of survival after cryosurgery
Figure 2  Kaplan-Meier survival curves after cryosurgery in relation to the size of metastases. P < 0.05 ( log rank 
test).
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At time of follow-up 25 of the 30 patients had developed recurrent disease. Disease free survival at 
one year was 35%, while disease free survival at 2 years was 7%. The median time to detection of 
recurrence was 7 months. Of the 25 patients with recurrent disease, 18 patients presented with hepatic 
recurrence. In 11 cases the liver was the only site involved. Extrahepatic recurrence was observed 
in 14 cases; lungs (6), colon/rectum (3), others (9). Six patients developed local recurrence at the 
site of cryosurgery. In four of these patients the cryo treated lesion was situated close to the portal 
bifurcation or inferior vena cava. In two of these cases there was some doubt during the procedure 
concerning the radicality of the freezing process. With regard to the total number of cryo treated 
lesions (n=69) in the series, the local recurrence rate was 9%. Three local recurrences occurred in 
tumours ≥4 cm.
Discussion
In only a minority of patients are colorectal liver metastases amenable to resection. Most patients 
have widespread liver involvement or extrahepatic disease which precludes any surgical approach. 
However, in a well-defined subgroup of patients with unresectable tumour, complete tumour 
clearance of the liver can be achieved by cryoablation of the liver metastases with or without combined 
resection of resectable lesions. This study has shown that an aggressive approach is rewarding in a 
selected group of patients and can result in significant prolongation of survival. Median survival was 
32 months despite inclusion in the study of patients with progressive disease during chemotherapy. 
These results compare favourable to those of chemotherapy for which a median survival has been 
reported between 12–17 months depending on the schedule used 25-28. Nevertheless patient selection 
may have contributed to the superior results in this series particularly as patients selected for this 
study had a limited number of metastases (no more than 10) and no extrahepatic disease. 
This study concurs with other studies on cryosurgery of colorectal liver metastases. In these series 1 
year survival rates vary from 72 to 88%, while 2 year survival rates between 52 and 72% are reported 
12,13,15,16,19,20,24. As in the present study cryoablation of unresectable lesions was generally combined with 
resection of those lesions that were amenable to surgery. The use of cryosurgery in combination 
with additional resection of resectable lesions increases the applicability of the method especially 
in patients with a combination of large lesions and small deposits 24. Since cryoablation seems less 
reliable in large metastases, resection is to be preferred for larger lesions and cryoablation for 
unresectable smaller lesions. Adam et al and Seifert and Morris reported that overall survival is 
significantly better in patients in whom the maximum diameter of the cryo treated lesion is smaller 
than 3cm 12,19. Temperatures reached at the edge of large lesions may be inadequate unless several 
cryoprobes are used in the same lesion.
Of all lesions treated by cryosurgery the overall local recurrence rate at the cryo site was 9%. This 
figure of local recurrence is low in comparison to a local recurrence rate of 44% as described by Adam 
et al 12. However, also others have reported local recurrence at the cryo site as low as 2.5% and 9% 
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15,17. Inadequate freezing was mainly observed in patients with lesions situated close to the inferior 
vena cava or portal bifurcation due to the heat sink effect of the high blood flow. Four patients with 
local recurrence at the cryo site had tumour situated close to these large vessels. Only two local 
recurrences were observed in lesions treated at other sites. 
In this study the overall disease free survival at 1 year was 35%. Most patients developed liver recurrence 
outside the cryo treated areas or presented with extrahepatic recurrence. These findings are in 
agreement with other series which report disease free survival rates varying from 15% at 15 months 
to 29% at 24 months 12,15,17,22,23. In contrast to several other series routine post-operative chemotherapy 
was not used in our study, although several series have reported significant benefits of this approach 
12,19. In a series of 116 patients treated by cryosurgery combined with intra-arterial chemotherapy Seifert 
and Morris observed a two year survival rate of 56% while earlier reports mention a 2 year survival 
rate of 13% in patients without intra-arterial chemotherapy 18,19. Most patients in our series, however, 
developed combined hepatic and extrahepatic recurrence which would make a case for combined 
intra-arterial and systemic chemotherapy after cryoablation. Although postoperative chemotherapy 
after liver surgery for colorectal metastases continues to be controversial 29. recent data from Kemeny 
et al suggest a potential benefit of postoperative chemotherapy by combined administration of intra-
arterial FUDR and systemic 5 FU- leucovorin 30. 
Cryoablation of liver metastases can be considered a safe procedure 12-24. The main complication in 
this series was abdominal abscess formation near the cryo treated area. In all cases percutaneous 
drainage could be performed. Postoperative hospital stay was mainly related to the extent of the 
accompanying hepatic resection. 
In patients with a limited number of unresectable colorectal liver metastases local cryoablation may 
be an attractive alternative to chemotherapy. Local tumour destruction should be considered as a 
complement to hepatic resection in order to obtain complete tumour clearance of the liver. Recently, 
radiofrequency has emerged as a new therapeutic option for local destructive therapy of liver 
metastases 31,32. This treatment should likewise be considered complementary to hepatic resection. 
However, with more widespread use of local tumour destructive techniques, randomised trials to 
compare chemotherapy with an aggressive surgical approach should be initiated in order to judge the 
potential benefit of local tumour destruction in unresectable colorectal liver metastases. 
References
1. Gilbert HA, Kagan AR: Metastases: Incidence, detection and evaluation without histologic confirmation. In 
Weiss L, ed: Fundamental aspects of metastases. Amsterdam, The Netherlands: Elsevier, 1976: 385-405.
2. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: Impact of surgical 
resection on the natural history. Br J Surg 1990; 77: 1241-6.
3. Hughes KS, Simons R, Songhorabodi S, Adson MA, Ilstrup DM, Fortner JG et al. Resection of the liver for 
colorectal carcinoma metastases: a multi-institutional study of indications for resection. Surgery 1988; 103: 
278-88.
4. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 
19: 59-71.
Joris Joosten.indb   57 13-11-2008   15:15:28
5
Chapter 4 
5. Fong Y, Cohen AM, Fortner J.G, Enker WE, Turnbull AD, Coit DG et al. Liver resection for colorectal 
metastases. J Clin Oncol 1997; 15: 938-46.
6. Elias D, Cavalcanti A, Sabourin JC, Lassau N, Pignon JP, Ducreux M et al. Resection of liver metastases from 
colorectal cancer: the real impact of the surgical margin. Eur J Surg Oncol 1998; 24: 174-9.
7. Taylor M, Forster J, Langer B, Taylor BR, Greig PD, Mahut C. A study of prognostic factors for hepatic resection 
for colorectal metastases. Am J Surg 1997; 173: 467-71.
8. Tranberg K, Bengmark S. Metastatic tumors of the liver. In: Blumgart L, ed. Surgery of the liver and biliary 
tract. Edinburgh, United Kingdom: Churchill Livingstone, 1994:1385-97.
9. Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D et al. Resection of nonresectable liver 
metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509-22.
10. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic 
resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-18. 
11. Nordlinger B, Quilichini MA, Parc R, Hannoun L, Delva E, Huguet C. Hepatic resection for colorectal liver 
metastases. Influence on survival of preoperative factors and surgery for recurrence in 80 patients. Ann Surg 
1987; 205: 256-63.
12. Adam R, Akpinar E, Johann M, Kunstlinger F, Majno P, Bismuth H. Place of cryosurgery in the treatment of 
malignant liver tumors. Ann Surg 1997; 225: 39-50.
13. Weaver ML, Ashton JG, Zemel R. Treatment of colorectal liver metastases by cryotherapy. Sem Surg Oncol 
1998; 14: 163-70.
14. Rubinsky B, Lee CY, Bastacky J, Onik G. The process of freezing and the mechanism of damage during hepatic 
cryosurgery. Cryobiology 1990; 27: 85-97.
15. Ravikumar TS, Kane R, Cady B , Jenkins R, Clouse M, Steele G Jr. A 5-year study of cryosurgery in the treatment 
of liver tumors. Arch Surg 1991; 126:1520-4.
16. Shafir M, Shapiro R, Sung M, Warner R, Sicular A, Klipfel A. Cryoablation of unresectable malignant liver 
tumors. Am J Surg 1996; 171: 27-31.
17. Crews KA, Kuhn JA, McCarty TM, Fisher TL, Goldstein RM, Preskitt JT. Cryosurgical ablation of hepatic 
tumors. Am J Surg 1997; 174: 614-8.
18. Preketes AP, Caplehorn JRM, King J, Clingan PR, Ross WB, Morris DL. Effect of hepatic artery chemotherapy 
on survival of patients with hepatic metastases from colorectal carcinoma treated with cryotherapy. World J 
Surg 1995; 19: 768-71.
19. Seifert JK, Morris DL. Prognostic factors after cryotherapy for hepatic metastases from colorectal cancer. 
Ann Surg 1998; 228: 201-8.
20. Seifert JK, Junginger T, Morris DL. A collective review of the world literature on hepatic cryotherapy. J R Coll 
Surg Edinb 1998: 43: 141-3.
21. Johnson LB, Krebs TL, Van Echo D, Plotkin JS, Njoku M, Wong JJ et al. Cytoablative therapy with combined 
resection and cryosurgery for limited bilobar hepatic colorectal metastases. Am J Surg 1997; 174: 610-3. 
22. Onik G, Rubinsky B, Zemel R, Weaver L, Diamond D, Cobb C et al. Ultrasound-guided hepatic cryosurgery in 
the treatment of metastatic colon carcinoma. Cancer 1991; 15: 901-7.
23. Weaver M, Atkinson D, Reuben Zemel R. Hepatic cryosurgery in treating colorectal metastases. Cancer 1995; 
76: 210-4. 
24. Hewitt PM, Dwerryhouse SJ, Zhao J, Morris DL. Multiple bilobar liver metastases: cryotherapy for residual 
lesions after liver resection. J Surg Oncol 1998; 67: 112-6.
25. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with 
bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301-8.
26. Köhne CH, Schöffski P, Wilke H, Käufer C, Andreesen R, Ohl U et al. Effective biomodulation by leucovorin 
of high-dose infusion fluorouracil given as weekly 24-hour infusion: results of a randomized trial in patients 
with advanced colorectal cancer. J Clin Oncol 1998; 16: 418-26.
27. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH et al. Phase II study of 
fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group Study. J Clin 
Oncol 1995; 13:1303-11.
Joris Joosten.indb   58 13-11-2008   15:15:28
5
Long term results of treating hepatic colorectal metastases with cryosurgery
28. Bleiberg H, de Gramont A. Oxaliplatin plus 5-fluoroucil: clinical experience in patients with advanced 
colorectal cancer. Semin Oncol 1998; 25: 32-39.
29. Lorenz M, Müller HH, Schramm H, Gassel HJ, Rau HG, Ridwelski K et al. Randomized trial of surgery versus 
surgery followed by adjuvant hepatic arterial infusion with 5- fluorouracil and folinic acid for liver metastases 
of colorectal cancer. Ann Surg 1998; 228: 756-62.
30. Kemeny N, Huang Y, Cohen A, Shi W, Conti JA, Brennan MF et al. Hepatic arterial infusion of chemotherapy 
after resection of hepatic metastases from colorectal cancer. N Eng J Med 1999; 341; 2039-48.
31. Solbiati L, Goldberg SN, Ierace T, Livraghi T, Meloni F, Dellanoce M et al. Hepatic metastases: percutaneous 
radio-frequency ablation with cooled tip electrodes. Radiology 1997; 205: 367-73.
32. Curley SA. Izzo F, Delrio P, Ellis LM. Granchi J, Vallone P et al. Radiofrequency ablation of unresectable 
primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 1999; 230: 1-8.
Joris Joosten.indb   59 13-11-2008   15:15:29
Joris Joosten.indb   60 13-11-2008   15:15:32
Chapter 5
Cryosurgery and radiofrequency ablation for 
unresectable colorectal liver metastases
Eur J Surg Oncol 2005; 31: 1152-9
J Joosten
G Jager
W Oyen
Th Wobbes
T Ruers
Joris Joosten.indb   61 13-11-2008   15:15:35
62
Chapter 5
Joris Joosten.indb   62 13-11-2008   15:15:35
63
Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases
Summary
Aims	 To report immediate local treatment efficacy and long-term results of cryosurgical ablation 
(CSA) and radiofrequency ablation (RFA) in patients with colorectal liver metastases not eligible for 
resection. 
Methods 58 patients with unresectable colorectal liver metastases were included. Under ultrasound 
guidance, CSA or RFA were performed with or without concomitant resection. CT scanning and FDG-
PET were used to determine local efficacy of the ablative procedure.
Results Median follow-up was 26 and 25 months for CSA and RFA, respectively. One and 2- year survival 
rates were 76% and 61% for CSA and 93% and 75% for RFA respectively.
In a lesion based analysis, the local recurrence rate was 9% after CSA and 6% after RFA. Complication 
rates were 30% and 11% after CSA and RFA, respectively ( p = 0.052). 
In a subgroup analysis on 43 patients with 104 ablated lesions, CT scan immediate after treatment was 
not able to predict local treatment failure, whereas FDG- PET scan within 3 weeks after local ablative 
treatment predicted 6 of the 7 local recurrences. 
Conclusions In patients with unresectable colorectal liver metastases, CSA and RFA can be used either 
alone or as an effective adjunct to resection in achieving complete tumour clearance of the liver. 
More widespread use of these techniques seems promising but requires further investigation in 
randomised trials comparing local ablative treatment with chemotherapy.
Introduction
Until now resection offers the highest chance of cure in patients with colorectal liver metastases. 
After resection a 5-year survival rate of up to 40 per cent is described 1. However, only 10-15 per cent 
of patients with liver metastases are eligible for resection. Extrahepatic disease, patient factors and 
tumour characteristics (number and site of metastases) can result in unresectable disease 2-4. 
When number and localization of metastases are the cause of unresectable disease, local ablative 
techniques such as cryosurgical ablation (CSA) and radiofrequency ablation (RFA) may offer an 
alternative treatment option with possible prolongation of survival. 
Cryosurgery is a long known ablative technique in which the application of extreme low temperatures 
to tumour tissue leads to protein denaturation and cellular dehydration, eventually resulting in 
tumour cell destruction 5-6. Several studies have described the feasibility and efficacy of cryosurgery 
in the treatment of unresectable colorectal liver metastases 7-9. More recently, radiofrequency 
ablation has been proposed as a successful treatment option in case of unresectable colorectal 
liver metastases. Hyperthermia with temperatures above 50° C will lead to immediate cell death 
and tumour destruction. Different groups have reported on the effects and safety of radiofrequency 
ablation, suggesting superior results compared to cryosurgery 10-13. 
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Morbidity and efficacy of these different local tumour ablative techniques are, however, difficult 
to compare because most reports include different patient selection criteria, different treatment 
protocols and sometimes even different types of tumour. Accordingly, the extent of liver disease 
treated in the different series varies significantly which directly influences data on morbidity, disease 
free and overall survival 14-16. Controlled studies comparing both techniques in well-defined selected 
patients are lacking.
The aim of this study is to compare the immediate effects and long-term results of cryoablation and 
radiofrequency therapy in a uniform group of patients with unresectable colorectal liver metastases.
Patients and Methods
Patient characteristics
Between January 1994 and June 2003, a consecutive series of 58 patients was identified from 
our prospective colorectal liver metastases database that underwent local ablative therapy for 
unresectable liver metastases. 
Patients with documented colorectal liver metastases who met the following criteria were considered 
for local ablative therapy: 1) metastases confined to the liver and judged unresectable due to extent of 
disease or localization, 2) CSA or RFA alone or in combination with resection should allow complete 
tumour eradication. 
The extent of disease was determined by abdominal spiral computed tomography (CT), chest CT scanning 
and later also by FDG-PET. Barium enema or colonoscopy were performed to exclude colorectal tumour 
recurrence. Routine laboratory tests were evaluated including liver function and CEA.
Table 1   Patient and tumour characteristics of all lesions
CSA group RFA group
Number of patients 30 28
Male : Female 19 : 11 18 : 10
Mean age (range) 62 yr  (45-79) 64 yr  (52-83)
Synchronous/metachronous 16 : 14 21 : 7 *
Median interval primary tumour and metachronous metastases (range) 12.5 mo  (7-29) 12 mo  (7-24)
Median time from detection metastases to CSA or RFA (range) 5.5 mo  (1-41) 5.5 mo  (1-42)
Median number of all lesions per patient (range) 3  (1-10) 3  (1–12)
Median diameter of all lesions per patient (range) 2 cm  (1-18) 2 cm  (1-9)
Median follow-up (range) 26 mo  (9-73) 25 mo  (1-50)
All lesions in 58 patients, individual lesions were either treated by local ablation or resection, * p value 0.086 (Chi-square test)
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In the first 30 consecutive patients local ablative therapy consisted of cryoablation ± resection 
(CSA group), in the last 28 patients radiofrequency ± resection (RFA group) was performed. Patient 
characteristics and data on all lesions encountered, either treated by local ablation or resection, 
are given in table 1. Patient treated by CSA ± resection (CSA group) and patients treated by RFA 
± resection (RFA group) were comparable for sex, age, total number of lesions and time interval 
between detection of metastatic disease and local ablative therapy. Both groups differed to some 
extent with regard to the time of metastatatic disease (synchronous versus metachronous). When 
synchronous was defined as occurrence of metastases within 6 months after the primary tumour, 
75% of the metastases in the RFA group had a synchronous occurrence compared to 53% in the CSA 
group (p=0.086). Patients in the CSA group tended to have a slightly higher score according to the 
prognostic scoring system as defined by Fong et al (Table 2) 4. 
Table 2  Distribution of prognostic factors 
Score CSA group (n=30) RFA group (n=28)
0-1 2 7
2-3 23 21
4-5 5 0
According to prognostic scoring system of Fong et al [4]: Each of the following risk factor is one point: node positive primary, disease free interval < 
12 months, > 1 tumour, largest tumour size > 5 cm, CEA > 200 ng/ml
Operative procedure 
All ablative procedures were performed using an open surgical approach. The abdominal cavity was 
explored thoroughly to exclude extrahepatic disease and the extent of liver involvement was mapped 
out by careful palpation and intra-operative ultrasound. During all surgical procedures resection was 
considered as the treatment of choice. When adequate resection of all tumour lesions could not 
be achieved patients were included in the study and the decision was taken to perform either local 
ablative therapy alone or to use local tumour ablation in combination with resection of resectable 
tumour deposits. In case resection was performed, a tumour free margin of at least 10 mm was 
achieved in most patients. 
After operation and application of local tumour ablation, patients did not receive any routine 
chemotherapy. 
Technique of cryoablation and radiofrequency
After localisation of the liver metastases the cryoprobe or radiofrequency needle was introduced under 
ultrasound guidance into the centre of the tumour avoiding major vascular and biliary structures. 
Cryosurgery was performed with a LCS 2000 apparatus (Spembly Medical Hampshire, England; 
Candela Corporation, Eindhoven, The Netherlands). During the freezing process continuous 
ultrasound monitoring of the lesion was carried out to assure that the “ice ball”, visible as a hypo-
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echogenic area around the tip of the cryoprobe, exceeded the diameter of the lesion by about 1 
cm. Per lesion two freeze-thaw cycles of 20 minutes freezing each were performed. Inflow occlusion 
(Pringle manoeuvre) was sometimes used to increase the efficacy of the freezing process. 
Radiofrequency was performed using a Radionics RF generator, model CC-1 (Radionics, Burlington 
MA). Generally for lesions < 2 cm in diameter a single needle cooled tip electrode was used, for 
lesions > 2 cm a cooled tip cluster-electrode was used. The process of tumour ablation was directly 
monitored by ultrasound. As radiofrequency energy was applied to the electrodes, a hyperechoic 
focus developed around the electrode. Radiofrequency was considered successful when all tumour 
tissue was included in the hyperechoic area including a rim of normal tissue of about 1 cm. After 
electrode insertion, each application of radiofrequency energy lasted for 10-15 minutes.
Postoperative follow-up
Within 3 weeks after local ablative treatment the following investigations were performed: spiral 
abdominal CT, serum CEA measurements and later during the study period FDG-PET imaging. These 
postoperative investigations were used to determine treatment efficacy and became the reference 
for further follow up investigations. After these initial examinations, follow up consisted of spiral 
abdominal CT, chest CT, serum CEA and FDG-PET examination at 6 weeks post treatment and every 3 
months thereafter. Regular follow-up was reduced to twice yearly after 3 years. The median follow-up 
after RFA was 25 months, for comparison of results the data presented after follow up of cryosurgery 
are restricted to a median follow up of 26 months. 
Disease free survival was defined as the period between local tumour ablation and the moment 
recurrent disease became apparent on spiral abdominal CT or chest CT. In case there was any 
doubt about recurrence at the site of CSA or RFA, an ultrasound-guided biopsy was performed for 
histological examination. In the event of new liver deposits, subsequent resection or local ablative 
therapy was performed whenever possible. Chemotherapy was started only when recurrent disease 
was not amenable to resection, cryosurgery or radiofrequency ablation. 
Imaging
CT scan
CT examination from abdomen and chest were performed with a spiral CT scanner Somatom Volume 
Zoom (Siemens Erlangen, Germany). The liver was scanned before and 70 seconds after the start of 
intravenous contrast injection. The area of local tumour ablation appears on the initial CT images as a 
sharply demarcated hypoattenuated, nonenhanced area, which decreases in size on follow up. A faint, 
irregular, hypoattenuated area around the margins of the ablated tumour that increased in size on 
follow up scans was interpreted as residual tumour. 
18F-FDG-PET-scanning
FDG-PET equipment became available for the study in April 1998. A dedicated PET-scanner (ECAT-
ART or ECAT EXACT, Siemens/CTI, Knoxville, TN, USA) was used for data acquisition. After successful 
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CSA or RFA, areas of focal FDG accumulation become photopenic. Areas of focal FDG accumulation 
after CSA or RFA greater than background activity were interpreted as being pathologic and highly 
suspicious for tumour residue or recurrence.
Statistics
Patient survival rates were estimated using Kaplan-Meier analysis. For comparison of differences in 
quantitative and ordinal variables between groups Student’s t-test and Chi Square test was used. 
Group differences for survival analysis were analysed with the log-rank test. P < 0.05 were considered 
statistically significant. 
Results
Surgical procedure
Amongst all lesions encountered in 58 patients, a total 69 lesions was treated by cryosurgery and 
72 by RFA. The characteristics of the lesions treated by local tumour ablation are given in table 3. 
The number of nodules per patient treated by cryosurgery ranged from 1-7, with a median of 2. The 
number of RFA lesions treated per patient varied from 1–8, with also a median of 2 (p=0.52). In the 
CSA group 22 of 69 lesions were greater than or equal to 4 cm compared to 6 out of 72 in the RFA 
group (p=0.00001). In all patients the same policy was followed. This means that, when possible, 
large lesions were generally resected, while remaining smaller lesions, which could not be resected 
because of anatomical considerations, were treated by local ablation. In the CSA group 23 patients 
were treated by such combined approach, versus 10 patients in the RFA group (p < 0.05). In all other 
cases CSA or RFA were used as single treatment.
Table 3  Treatment characteristics of lesions treated by local ablation
CSA group RFA group
Number of patients treated by local ablation and resection 
Type of resection: - wedge/1 segment
 - 2 or more adjacent segments
 - multiple resections
 23 
	 11
	 3
	 9
 10 *
	 5
	 3
	 2
Number of patients treated by local ablation alone  7  18 
Total number of lesions treated by resection or ablation  115  94
Total number of lesions treated by ablation  69  72
Median diameter of lesions treated by ablation (range)  3 cm (1-9) 3 cm (1-5)
Number of lesions ≥ 4cm treated by ablation  22  6 **
* p < 0.05 (Chi-square test), **p<0.05(Chi-square test)
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Mortality and morbidity
There was one postoperative death in both groups. One patient died of an acute myocardial infarction 
14 days after an uncomplicated cryosurgical procedure. The other patient died of sepsis and irreversible 
multi organ failure after a combined procedure of an extended liver resection and radiofrequency 
ablation. 
In the CSA group, 2 patients experienced a significant haemorrhage with clinical consequences. 
One patient had to be re-operated because of haemorrhage from a treated lesion, another patient 
required packing of the liver during the procedure due to hepatic cracking of the ice ball associated 
with bleeding. No significant haemorrhage was observed in the RFA group. Four patients in the CSA 
group and three in the RFA group developed an abscess in the treated area. All were treated by 
percutaneous drainage under ultrasonic guidance. Three CSA patients developed pneumonia after the 
cryosurgery procedure. In both groups right pleural effusion was encountered in several patients due 
to the irritative process beneath the diaphragm. This pleural effusion was generally asymptomatic and 
resolved spontaneously. Total morbidity rate in the CSA group was 30% versus 11% in the RFA group (p 
= 0.052). The median hospital stay after CSA was 10 days, after RFA treatment 8.5 days. 
Efficacy of local tumour control
During follow up, local recurrence at the ablated site was encountered in 6 of the 69 CSA treated 
lesions (9%) and 4 of the 72 RFA treated lesions (6%), which relates to 20% of the patients in the CSA 
group and to 14% of the patients in RFA group. For all lesions with a diameter less than 4 cm, local 
recurrence rates for CSA (3/47) and RFA (4/66) were similar (6%). For lesions equal to or larger than 
4 cm, the local recurrence rate in the CSA group was 14% (3/22). Four CSA lesions and all RFA lesions 
that developed local recurrence were situated against large vessels. All local recurrences developed 
within 12 months after treatment.
Imaging after local tumour ablation: CT scan and FDG-PET  
To investigate the most accurate and predictive imaging technique after local tumour ablation, results 
form spiral CT scan and FDG-PET were compared from the moment FDG-PET became available during 
the study period. 
43 Patients (17 CSA, 26 RFA) with in total 104 lesions (36 CSA, 68 RFA) were followed by spiral CT scan 
as well as FDG-PET. None of the 7 local treatment failures, which were encountered in this subgroup 
analysis, was predicted by CT scan immediate after treatment. CT scan 4 months after treatment 
predicted only 1 of the 7 cases that developed local recurrence at the treatment area. FDG- PET scan 
within 3 weeks after local ablative treatment predicted 6 of the 7 recurrences. One local recurrence 
was detected on FDG-PET 3 months after treatment. The negative predictive value at three months for 
the detection of local treatment failure with a negative FDG-PET was 100%. Since FDG-PET showed 
one false positive result due to focal infection, the positive predictive value for the detection of local 
treatment failure is 88%.
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Survival 
Overall survival at one, two and three years for all 58 patients is 84, 68 and 46% respectively. At a 
median follow-up of 26 months, 14 patients have died in the CSA group, 13 due to metastatic disease 
and one postoperative death (myocardial infarction). After cryosurgery overall survival rate at 1 year 
is 76%, at 2 years 61% (Figure 1). At a median follow up of 25 months, 10 patients have died in the RFA 
group including one postoperative death. After RFA, the 1- and 2-year survival rate is 93% and 75% 
respectively. Overall survival for both groups is not statistically different (p = 0.37). Moreover, in this 
series there is no significant difference in survival between patients treated by local ablation alone 
and patients treated by local ablation combined with resection (p = 0,55, data not shown).
At this stage 25 of the 30 CSA patients and 19 of the 28 RFA have developed recurrent disease. Disease 
free survival at 1 year is 37% in the CSA group and 38% the RFA group (figure 2). The median time to 
detection of recurrence is 7 months in the CSA group versus 6 months in the RFA group (p = 0.60). The 
pattern of recurrent disease is comparable between both groups (Table 4). Including local recurrence 
at the ablated site, 18 CSA patients (60%) and 13 (46%) RFA patients showed hepatic recurrence. The 
liver was the only site of recurrence in 11 (37%) patients in the CSA group and in 6 patients in the RFA 
group (21%). Extrahepatic recurrence was observed in 14 CSA (47%) and 13 RFA (46%) cases. 
Figure 1  Kaplan-Meier curves of survival after cryosurgery and radiofrequency ablation. For difference between 
CSA and RFA group p = 0.37 (log-rank test).
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Figure 2  Kaplan-Meier curve of disease free survival after cryosurgery and radiofrequency ablation. For 
difference between CSA and RFA group p = 0.87 (Log-rank test)
Table 4  Pattern of recurrence
CSA group (n=30) RFA group (n=28)
Hepatic  18  13 
Liver only  11  6 
At CSA or RFA site  6  4 
Extrahepatic  14  13 
Lung  6  9 
Intestine  3  4 
Other  9  4 
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Discussion 
For patients with colorectal liver metastases surgical resection offers the best chance for cure. In 
most patients with colorectal liver metastases, however, resection cannot be performed either 
because of extensive liver involvement or unfavourable located tumour deposits. It is in these 
patients in whom local ablative techniques, such as cryosurgery or radiofrequency, may be helpful 
to achieve local tumour control potentially leading to prolongation of survival 7-13. Although local 
ablative techniques, such as cryosurgery and radiofrequency ablation, have been studied for several 
years, direct comparison of both techniques has only been made in a limited number of studies with 
often a heterogeneous group of patients. 14-16. The present study directly compares the immediate and 
long-term results of cryosurgery and radiofrequency in a uniform consecutive cohort of patients with 
unresectable colorectal liver metastases. 
Local tumour control
It is demonstrated that both techniques can result in effective local tumour control. For lesions below 
4 cm in diameter local recurrence at the treated site was 6% for both CSA and RFA. For comparison, 
local recurrence after resection is been reported below 2% 25. Our data on local recurrence are 
comparable to other studies in which local recurrence for tumours below 4 cm varies between 2 and 
18% 8-10,13. For tumours over 4 cm in diameter a local recurrence rate after CSA of 14% was observed. 
This figure compares favourably to results reported for RFA for lesions over 4 cm in diameter. Several 
studies report local recurrence rates of 30% and more after RFA for these lesions. For this reason we 
were reluctant to treat lesions over 4 cm with RFA. 
Three other non-randomised studies have been performed to compare the treatment efficacy of 
CSA and RFA for unresectable hepatic tumours 14-16. Our results are in concordance with those of 
Bilchick et al. who compared RFA and CSA treatment for unresectable hepatic tumours 14. Overall 
local recurrence rate in this series was 5% and 3% for CSA and RFA, respectively. However, for lesions 
over 3 cm local recurrence rates for RFA were significantly higher than for CSA. After RFA 38% of the 
patients developed local recurrence versus 17% of those treated by CSA. In another study by Pearson 
et al a diversity of liver tumours was treated either by CSA or RFA 15. In this series local recurrence 
was identified in 13.6% of the patients treated with CSA and in 2.2% in those treated by RFA. As a 
result the authors strongly preferred RFA. In a third study, Adam et al. compared percutaneous CSA 
and percutaneous RFA in a variety of liver tumours 16. Local recurrence for metastatic lesions was 
significantly higher in the CSA treated lesions (71%) than in those lesions treated by RFA (19%). 
Post- treatment monitoring
Earlier studies described the feasibility of FDG-PET scanning in the surveillance of hepatic tumours after 
ablative treatment 17,18. Also this study shows that FDG-PET can be used as a reliable marker in evaluating 
the efficacy of the ablative treatment. Tumour recurrence indicated by FDG-PET can be an early indication 
for repeated tumour ablation and can potentially contribute to better local tumour control.
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Mortality and Morbidity
An apparent advantage of RFA over CSA is the lower treatment related complication rate. The overall 
reported complication rate after RFA is 8.9% 19. This is significantly lower than for CSA, for which 
complication rates up to 40% are reported 20. Also in our study RFA showed fewer treatment related 
complications than CSA. Morbidity after RFA was 11% and consisted mainly of abscess formation in 
the treated area. Abscess formation is a well known complication which is observed in 5% to 25% 
of the cases 19. Generally it can be managed by percutaneous drainage. We did not encounter any 
haemorrhages after RFA which is in strong contrast to CSA where bleeding is an often encountered 
complication during or after the freezing process. Besides bleeding we more often encountered 
pulmonary complications after CSA. However, this higher rate of pulmonary complications may 
be due to the fact that in the CSA group more patients were treated with extensive resection in 
combination with local tumour ablation than in the RFA group. 
Survival
There is no significant difference in survival between both treatment modalities. Survival after 1 year 
is 76% for cryosurgery and 93% for RFA patients. Two year’s survival is 61% and 75% respectively. Our 
figures correspond well with other reports on local ablative therapy for colorectal liver metastases. 
After cryosurgery for unresectable colorectal liver metastases, 1-year overall survival rates are reported 
between 77-95%, overall 2-year survival rates vary from 52-78% 7,21-23. For RFA comparable figures are 
observed with a 1 -year overall survival rate varying from 58% to 93%, while the 2 -year overall survival 
rate ranges from 50 and 69% 13,16,24,25. 
It is remarkable that when a prognostic scoring system is applied as in the present study, overall 
survival figures after local tumour ablation come close to overall survival data reported after hepatic 
resection. According to the prognostic scoring system of Fong et al most of the patients treated in 
the present series show a score of 2-3 4. Patients in this category show 1- and 2-year overall survival 
rates after hepatic resection of about 90% and 70%, which is almost comparable to overall survival 
obtained after local tumour ablation. 
In concordance to other reports, 1-year disease free survival after local tumour ablation is only 37% 
and 38% after CSA and RFA, respectively. The vast majority of recurrences occur within other parts of 
the liver outside the treated areas or at extrahepatic sites. This implies more widespread disease than 
originally detected at the time of local ablative treatment. 
Hence, the question arises whether in these patients with more widespread and unresectable disease 
treatment by local tumour ablation may be of any beneficial effect on overall survival. Although 
median overall survival times after local tumour ablation of unresectable colorectal liver metastases 
(32-34 months) have been claimed to be better than with chemotherapy (17-19 months), the superior 
results reported after local tumour ablation may certainly be due to patient selection. In order to 
determine the place of local tumour ablative therapy in these patients with unresectable colorectal 
liver metastases controlled clinical trials are highly needed. At this moment the only randomised 
clinical trial comparing RFA plus chemotherapy with chemotherapy alone in patients with unresectable 
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colorectal liver metastases is the EORTC–CLOCC trial. Only this trial can ultimately proof the 
additional value of local ablative therapy in patients with unresectable colorectal liver metastases. 
Surgeons and medical oncologists should strongly be encouraged to participate in this initiative. 
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Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases; a prospective study
Abstract
Background	There is a growing interest for the use of local ablative techniques in patients with non-
resectable colorectal liver metastases. Evidence on the efficacy over systemic chemotherapy is, 
however, extremely weak. In this prospective study we aim to assess the additional benefits of local 
tumour ablation. 
Methods	A consecutive series of 201 colorectal cancer patients, without extrahepatic disease, that 
underwent laparotomy for surgical treatment of liver metastases, were prospectively followed for 
survival and HRQoL. At laparotomy three groups were identified: patients in whom radical resection 
of metastases proved feasible, patients in whom resection was not feasible and received local ablative 
therapy, and patients in whom resection or local ablation was not feasible for technical reasons and 
who received systemic chemotherapy. 
Findings	Patients in the chemotherapy and in local ablation group were comparable for all prognostic 
variables tested. For the local ablation group overall survival at 2 and 5 years was 56% and 27%, 
respectively (median 31 months, n=45), for the chemotherapy group 51% and 15%, respectively (median 
26 months, n=39)(p=0.252). After resection these figures were 83% and 51%, respectively (median 61 
months, n=117)(p< 0.001). The median DFS after local ablation was 9 months, HRQoL was restored 
within 3 months. Patients after local ablation gained far more QALY’s (317) than in the chemotherapy 
group (165)(p< 0.001). 
Interpretation	Although overall survival did not reached statistical significance, the median DFS of 
9 months suggests a beneficial effect of local tumour ablation for non-resectable colorectal liver 
metastases. Moreover, compared with systemic chemotherapy more QALY’s were gained after local 
ablative therapy.
Introduction
In patients with colorectal liver metastases, resection offers the best chance of cure, with 5-year 
survival rates between 35%- 50% 1-5. In the majority of cases, however, liver metastases prove non-
resectable because of the high number of lesions or because of the location of the metastases. To 
these patients chemotherapy is generally offered, and a median overall survival up to 20 months can 
be achieved 6-9. 
In recent years, several techniques for local tumour destruction have emerged as an alternative 
treatment for patients with non-resectable colorectal liver metastases, e.g. cryoablation or 
radiofrequency 10-19. Local tumour ablation aims at selective destruction of tumour tissue without 
significantly intervening with liver anatomy. Initially, these techniques were used by surgeons when 
confronted with non-resectable metastatic disease at laparotomy. More recently, new techniques 
have become available for laparoscopic or percutaneous use. Although many methods proved to be 
safe, the impact on survival of local tumour ablative therapy in case of non-resectable disease is 
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still unclear 10-20. Several uncontrolled studies in patients with colorectal liver metastases showed 
effective local tumour control and median overall survival could be prolonged to over 30 months 
10,12,14,16,21,22. These results were claimed to be superior when compared to historical controls treated by 
chemotherapy. This may, however, certainly be biased by patient selection. In contrast to the general 
patient population treated by chemotherapy, patients selected for local tumour ablation have only a 
limited number of liver metastases without any extrahepatic disease. Hence, the essential question 
whether there is any benefit of local tumour treatment over systemic chemotherapy in patients with 
non-resectable colorectal liver metastases is still open for debate. 
In this comparative prospective study we opted to assess the additional benefit of local tumour 
ablation in a well-defined patient population. For this purpose we prospectively evaluated survival and 
health related quality of life from a consecutive cohort of patients that were selected for laparotomy 
and surgical treatment of their colorectal liver metastases. Patients that showed non-resectable liver 
metastases at laparotomy received either local tumour ablation or, when this was not feasible for 
technical reasons, systemic chemotherapy. 
Patients and methods
Study design and treatment algorithm
Between November 1995 and November 2004, a consecutive series of 201 patients received their first 
laparotomy in an attempt to cure metastatic disease confined to the liver. Patients were considered 
eligible for resection or local tumour ablation based on preoperative work-up by multislice CT of 
chest and abdomen, and colonoscopy or barium enema to exclude a new colorectal primary. 
All patients were treated and followed at the Radboud University Nijmegen Medical Centre according 
to standardized institutional protocols.
Following the application of a strict treatment algorithm, the three major groups could be identified 
at laparotomy: 1) Patients treated by resection. Resection was always considered the treatment of 
choice whenever negative resection margins could be obtained. Essentially, resection was performed 
for any number or location of metastases (uni-bilobar) as long as not more than 70% of liver needed 
to be removed. 2) Patients treated by local tumour ablation. Local treatment (by cryosurgery or 
radiofrequeny) was only performed when resection alone could not result in adequate treatment 
of all liver lesions. Local tumour ablation, either alone or in combination with resection, was only 
considered when complete tumor eradication of all liver lesions was judged possible. 3) Patients treated 
by systemic chemotherapy. Patients with metastases confined to the liver that could not be treated 
by resection or local tumour ablation because of purely technical reasons were further assigned to 
chemotherapy. Technically, resection was refrained from when negative resection margins could not 
be obtained or when more than 70% of the liver tissue had to be removed. Technical reasons to 
refrain from local tumour ablation were lesions too close to large vessels or main hepatic ducts, or 
lesions not accessible for local ablation. During the study period systemic chemotherapy consisted 
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of 5-fluorouracil (5-FU) and leucovorin in the first line and irinotecan in the second line. Oxaliplatin 
became part of first line treatment in 2001 and since 2005 bevacizumab was added to the standard 
chemotherapy regimen. 
During the study period systemic chemotherapy generally consisted of 5-fluoroucil and leucovorin in 
first line and irinotecan or oxaliplatin in second line.
Patients that were diagnosed with extrahepatic disease at laparotomy were excluded from further 
analysis since comparison to other patients groups was judged to be inappropriate (figure 1). 
Patients treated by resection or local tumour ablation did not receive any subsequent chemotherapy, 
unless non-resectable disease recurrence was encountered during follow-up. 
Surgical procedure 
When resection was performed, a tumour free margin of at least 10 mm was aimed for. For local 
tumour ablation, cryoablation (n=18) was used until 1999, thereafter local tumour ablation was 
performed by radiofrequency (n=27). All ablative procedures were performed using an open surgical 
approach. Cryosurgery was performed with a LCS 2000 apparatus (Spembly Medical Hampshire, 
England; Candela Corporation, Eindhoven, The Netherlands). Radiofrequency was performed using 
a Radionics RF generator, model CC-1 (Radionics, Burlington MA) according to manufacturer’s 
guidelines. During all ablative procedures, tumour destruction was directly monitored by ultrasound. 
Local tumour ablation was considered successful when all tumour tissue and a rim of normal tissue of 
about 1 cm was included in the treated area.
Figure 1  Study design and distribution of treatment groups
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Follow up
All patients were followed prospectively and documented for disease recurrence or death. No patients 
were lost to follow up. Follow up after resection or local tumour ablation consisted of a 3 monthly CEA 
test and abdominal CT and 6 monthly chest CT until 3 years after resection. Thereafter, follow up 
was reduced to a CEA test and ultrasound of the liver every 6 months. Patients that were treated by 
systemic chemotherapy, were followed according to the chemotherapy regimen used but received 
at least 3 monthly evaluations. In case of disease recurrence after resection or local tumour ablation, 
surgical treatment was considered the first choice for liver recurrence or pulmonary recurrence. In 
case surgical intervention was not feasible chemotherapy was started. After resection or local tumour 
ablation, disease recurrence was defined as any lesion on CT scan suspicious for recurrence of disease. 
Overall and disease free survival were defined as the time interval from the date of laparotomy to 
the date of death or disease recurrence, respectively. All deaths within hospital or within 30 days of 
surgery were considered as surgery-related mortality.   
Health-related quality of life (HRQoL) 
Patients were at random asked to consent in a prospective evaluation considering HRQoL. The study 
was approved by the local ethical committee. The instruments were completed preoperatively, 2–3 
weeks after the operation (discharge from the hospital is usually within ten days), and then every 3 
months until 1 year after the operation. 
Two validated (self-report) instruments were used, the EuroQol-5D (EQ-5D) and the European 
Organization for Research and Treatment of Cancer core questionnaire (EORTC QLQ C-30) 23. Based 
on the scores of the EQ-5D index quality-adjusted life years (QALYs) were computed. Here, QALYs are 
expressed as quality-adjusted days instead of years. 
Statistical analysis 
All data were analyzed with SPSS statistical software (version 12.0.1 for Windows, SPSS, Chicago). 
Patient survival rates were estimated using Kaplan-Meier analysis, evaluation of differences between 
two groups was performed with the log-rank test. Differences between groups were tested with 
Student’s t-test or ANOVA in case of continuous variables, differences of proportions were tested 
with Fisher exact test. P-values of less than 0.05 were considered statistically significant. 
For HRQoL analysis mean scores with standard deviations were computed. For the QALY estimations 
we used the actual dates of completion of the EQ-5D instrument to compute the time intervals 
between successive measurements. These intervals were multiplied with the mean value of the 
derived index scores of the EQ-5D instrument of the time period involved (approximation of the 
trapezium rule) 24.
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Results
In total 213 patients underwent laparotomy for surgical treatment of liver metastases. Twelve patients 
were found to have extrahepatic disease at laparotomy and were excluded from further analysis. Of 
the remaining 201 eligible patients, 117 (58.2%) patients underwent resection of the metastases, 45 
(22.4%) patients with non-resectable lesions were treated by local tumour ablation and 39 (19.4%) 
patients, not eligible for resection or local tumour ablation because of technical reasons, were treated 
by chemotherapy. Patients and tumour characteristics of the different treatment groups are given in 
table 1.
The local ablation group and the chemotherapy group were comparable for all prognostic indicators. 
The resection group differed significantly from the local ablation group and the chemotherapy group 
with regard to the number of metastases. The median number of lesions in the resection group was 1 
versus 4 in both other groups. For further comparison, the different treatment groups were analyzed 
according to the prognostic scoring system of Fong et al 25. The resection group showed a significantly 
better prognostic score compared to both other groups. No significant differences in prognostic 
scores were found between the local ablation group and the chemotherapy group, thereby allowing a 
direct comparison of outcome parameters between these groups.
Overall Survival
At the time of analysis (median follow up 61 months) 49 patients (42 percent) in the resection group 
had died, as compared with 30 patients (67 percent) in the local ablation group and 28 (72 percent) 
patients in the chemotherapy group. According to Kaplan Meier survival analysis, the 2 and 5-year 
overall survival in the resection group was 83 percent and 51 percent, respectively (figure 2). 
In the local ablation group these figures were 56 percent and 27 percent respectively, and in the 
chemotherapy group 51 percent and 15 percent, respectively. Median overall survival was 61 months 
(95% CI 41- 81 months) in the resection group, 31 months in the local ablation group (95% CI 20-42 
months) and 26 months in the chemotherapy group (95% CI 17 - 35 months). The difference in overall 
survival between the resection group and both other groups was statistically significant (p < 0.001). 
The difference in overall survival between the chemotherapy group and the group of patients treated 
by local tumour ablation did not reach statistical significance (p = 0.252).
Peri-operative mortality in the 162 patients undergoing surgical treatment of the liver metastases was 
3.7 percent. Four patients in the resection group died, one patient due to cardiac failure and 3 patients 
due to postoperative sepsis. Two patients in the local tumour ablation group died, one patient after 
radiofrequency plus extended resection due to postoperative sepsis and one patient due to acute 
myocardial infarction 14 days after an uncomplicated cryosurgical procedure. 
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Figure 2  Kaplan-Meier analysis of overall survival according to treatment group.
Figure 3  Kaplan-Meier analysis of disease free survival according to treatment group.
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Table 1  Patient and tumour characteristics.
Characteristic Resection 
(N = 117)
Local tumour ablation
(N=45)
Chemotherapy 
(N = 39)
Age - yr
 Median
 Range
61
24-80
61
45-84
61  NS
35-85
Sex - no. (%)
 Male
 Female
 66  (56.4)
 51  (43.6)
 29  (64.4)
 16  (35.6)
 22  (56.4) NS
 17  (43.6)
N stage primary - no. (%)
 Node -
 Node + 
 Unknown
 55  (47.0)
 61  (52.1) 
 1  (0.9)
 21  (46.7)
 24  (53.3)
 1  (2.2)
 16  (41.0) NS
 23  (59.0)
T stage primary - no (%)
 T 0
 T 1
 T 2
 T 3
 T4
 Unknown
 1  (0.9)
 2  (1.7)
 12  (10.3)
 90  (76.9)
 11  (9.4) 
 1 (0.9)
 0
 0
 5  (11.1)
 39  (86.7)
 1  (2.2)
 0  NS
 0 
 4  (10.3)
32  (82.1)
 3  (7.7)
Number of liver lesions *
 Median 
 Mean
 Range
1**
1.8
1 - 9
4
4.6
1 - 19
4   NS
4.6
1 - 17
Size of largest lesion (mm)
 Median 
 Mean 
 Range
38.5
44.9
8 -150
30
38
10 - 120
42  NS
47.9
10 - 180
Interval prim. tumour to metastases no (%)
 ≤ 12 months 
 > 12 months
 71  (60.7) ***
 46  (39.3)
 37  (82.2)
 8  (17.8)
 27  (69.2)
 12  (30.8)
CEA value - (μg/l)
 Median 
 Range
7.4
1 - 240
9.4
1 - 430
12.9 NS
1 - 760 
Fong score*
 0
 1
 2
 3
 4
 5
 11  (9.4) **
 38  32.5) 
 34  (29.1)
 29  (24.8)
 4  (3.4)
 0
 1 (2.2)
 1 (2.2)
 18  (40.0)
 20  (44.4) 
 5  (11.1)
 0
 3 (7.7) NS
 3 (7.7)
 13  (33.3)
 18  (46.2)
 1  (2.6)
 1  (2.6)
*As determined at laparotomy by inspection and ultrasound. Five prognostic variables are assigned one point: disease free interval from primary 
disease to metastases < 12 months, node-positive primary tumour, > 1 tumour, largest tumour size > 5 cm, CEA < 200 ng/ml. The total score ranging 
from 0 to 5 has been proven to be highly prognostic for long term outcome and can be used to compare groups of patients for base line prognostic 
variables (25).
** P < 0.005 for difference between resection group and other groups
*** P = 0.01 for difference between resection group and local ablation group 
Because rounding, not all percentages total 100. Statistically significant differences are indicated NS = not significant. (The local ablation group and 
the chemotherapy group did not show any significant difference for any of the parameters tested).
Joris Joosten.indb   85 13-11-2008   15:15:51
6
Chapter 6
Disease free survival 
At the time of analysis, 73 patients (62 percent) in the resection group had relapsed or died, as 
compared with 37 patients (82 percent) in the group treated by local tumour ablation. Disease free 
survival at 2 and 5 years in the resection group was 43 percent and 32 percent respectively, in the 
group treated by local tumour ablation these figures were 17 percent and 11 percent, respectively 
(figure 3). Median disease free survival in the resection group was 18 months (95% CI 13 – 23 months) 
as compared with 9 months (95% CI 3 – 15 months) in the group treated by local tumour ablation (p< 
0.001). 
The distribution of the first site of recurrence was similar in both groups (figure 4). Most recurrences 
occurred elsewhere in the liver outside the treated area or at extrahepatic sites. In the group treated 
by local tumour ablation, 5 patients developed a local recurrence at the ablated site (11 percent), 
compared with one patient that showed local recurrence at the resection site after resection (0.9 
percent) (p < 0.004). Analyzed on a lesion basis, local recurrence after local tumour ablation was 4.1 
percent. Six lesions (in 5 patients) out of 146 lesions treated by local tumour ablation showed a local 
recurrence. 
None of the patients that were initially treated by chemotherapy or ablation underwent secondary 
resection of the liver metastases. After chemotherapy, in 2 out of the 39 patients complete response 
was observed without any surgical intervention afterwards
Health-related quality of life (HRQoL)
In total 109 patients participated in the HRQoL analysis. At baseline, the resection group consisted 
of 53 patients, the local ablation group of 29 patients and the chemotherapy group of 27 patients. At 
baseline the mean total scores in the different groups were similar. Figure 5 presents the HRQoL as 
measured by the EQ-5D VAS score and the EORTC physical functioning score. The latter comprises 
an objective score on physical functioning while the EQ-5D VAS score represents overall HRQoL 
from the patient perspective. Both scores show a clear decrease 3 weeks after operation compared 
to baseline. Three months after operation, patients treated with local tumour ablation and resection 
returned to baseline levels. For patients treated by chemotherapy, HRQoL scores on EQ-5D VAS and 
on EORTC QLQ physical functioning remained lower as compared with the two other groups until the 
end of the assessment (12 months). For both scores, the difference between the local ablation group 
and the chemotherapy group was statistically significant (p< 0.05) on all time points, except for the 
first time point after surgery (3 weeks). Other HRQoL scores showed an identical pattern to the EQ-
5D VAS score and the EORTC physical functioning score (data not shown). 
During the first year after laparotomy, the number of QALYs generated for the resection, the local 
ablation and the chemotherapy groups were 283, 317 and 165, respectively (expressed in days in full 
health instead of years). For the chemotherapy group the number of QALY-days was significantly 
lower in comparison with the other two groups (P < 0.01). 
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Figure 4  Site of primary recurrence according to treatment group.
Figure 5  EQ-5D VAS (patients’ perspective) scores and EORTC QLQ physical functioning scores (Statistical 
significance between the groups local ablation and chemotherapy are depicted by ‘ asterisk ‘).
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Discussion
In the present study we evaluated the efficacy of local tumour ablation in patients with non-resectable 
colorectal liver metastases. Within the limitations of the study design, in a group of patients with 
non-resectable colorectal liver metastases and comparable prognostic parameters, we observed a 
trend towards improved survival for the treatment with local tumour ablation compared to treatment 
with chemotherapy, although this difference was statistically not significant. In patients treated by 
local tumour ablation median overall survival was 31 months, compared with 26 months for patients 
treated by chemotherapy. In this well-defined patient population treated by local tumour ablation 
without subsequent chemotherapy, median disease free survival was 9 months. After local tumour 
ablation, HRQoL scores were restored to baseline values within 3 months after the procedure, while 
the number of QALYs gained was substantially higher in the local ablation group compared with the 
chemotherapy group. These data are suggestive for a beneficial effect of local tumour treatment in 
patients with non-resectable disease. 
Within this study we complied with the widely accepted definition of surgical resectability of 
colorectal liver metastases, defined as essentially any number of metastases (uni-bilobar) as long as 
not more than 70% of liver needs to be removed 26. Only patients who did not fulfil these requirements 
were treated by local tumour ablation or chemotherapy. The decision to perform either local tumour 
ablation or chemotherapy was taken only on the basis of technical feasibility to perform local tumour 
treatment. In this way, we defined the best possible control group for local tumour ablative therapy. 
Patient characteristics, tumour load and the prognostic scores of the patients treated by local tumour 
ablation were fully identical to the group treated by chemotherapy. Moreover, patients treated by 
local tumour ablation did not receive subsequent chemotherapy until non-resectable recurrent 
disease was observed. 
Our data on overall survival after resection or local tumour ablation are comparable to others. Five-
year survival rates after resection of colorectal liver metastases has been reported between 35-50 
percent 2,3,5. Studies on long term survival after local tumour ablation, either by radiofrequency or 
cryoablation, report 4 year overall survival rates varying from 25% – 35%, with a median overall 
survival between 29 to 35 months 10,12,18,19,22. These results are mainly dependent on the number and size 
of the lesions treated rather than on the technique used 11,27,28,29,30,31. 
To our knowledge only one other study has made a direct comparison between results of local tumour 
ablation and chemotherapy 10. In this study by Abdalla et. al., radiofrequency of colorectal liver metastases 
was compared with chemotherapy in patients not eligible for surgical treatment at laparotomy 10. 
Survival after radiofrequency was significantly better than for chemotherapy but survival curves of 
radiofrequency and chemotherapy were converging and the authors questioned whether with longer 
follow up and with better chemotherapy the advantage would sustain. Our results demonstrate that 
in patients treated with local tumour ablation, without subsequent chemotherapy, a median disease 
free survival of 9 months is obtained. It is likely that such preferential effect of local tumour ablation on 
overall survival will continue to sustain even with improvements in systemic chemotherapy. 
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For patients treated within the chemotherapy, the median overall survival was 26 months. This 
figure is obviously biased by the fact that it concerns a group of patients with better prognostic 
factors compared to the general population of patients with advanced colorectal cancer, i.e. limited 
hepatic metastases without extrahepatic involvement. Although it is likely that more recent forms 
of chemotherapy may further improve the results in these patients, it should be realized that these 
improvements will also apply for patients treated by local ablation once these patient show recurrence 
of disease. The impact of chemotherapy given after recurrence of disease may even be substantial, 
given the marked difference between the median disease free survival (9 months) and the median 
overall survival (31 months) after local tumor ablation.
Ten percent of the patients treated by local tumour ablation showed local recurrence at the site of 
treatment. This is in agreement with literature in which local recurrence rates vary from 0%-50% 10,14-
16,21,22,27,31,32. On a lesion basis, only 4.1% of the lesions treated by local ablation showed local recurrence. 
This low percentage may well be due to the fact that 95% of the lesions treated were smaller than 4 
cm. It has well been described that local tumour ablation by either radiofrequency or cryoablation is 
far less efficient for lesions larger than 3-4 cm 12,31,33. Although technical advances are rapidly evolving, 
it seems reasonable with the present equipment to limit local tumour destruction to tumours smaller 
than 4 cm. 
Worldwide there is a fast and growing interest for the use of local ablative techniques in patients 
with colorectal liver metastases. Conclusive evidence is, however, still remarkably weak for the 
large scale on which these procedures are used at present. Only one randomized trial is currently 
being performed investigating the efficacy of radiofrequency for the treatment of unresectable 
colorectal liver metastases. In this EORTC study (CLOCC) overall survival after radiofrequency 
plus chemotherapy is compared with chemotherapy alone. Advocates of radiofrequency ablation 
often criticize such randomized studies pointing to the successful results of radiofrequency with 
regard to local tumor control. In the present study we were able to identify two comparable patients 
groups that were either treated by chemotherapy or by local tumor ablative therapy. We show that 
for patients with unresectable colorectal liver metastases, the advantages of local tumor control by 
radiofrequency may be subtle and may not inevitably lead to large and significant differences in 
overall survival. This observation strongly underlines the urge for randomized trials, especially at a 
time when purchases of health care are looking for evidence based therapy. In the absence of data 
from such randomised controlled trials, we provide the best evidence possible on the efficacy of local 
tumour ablative therapy in patients with non-resectable colorectal liver metastases. 
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Abstract
Introduction	In selected patients with isolated colorectal lung- or liver metastases resection can provide 
an increase in overall survival and even cure. Here, we evaluate whether also patients with combined 
or sequential metastatic disease to liver and lung may still be candidate for surgical resection. 
Methods	 From 1997 till 2006 39 patients underwent pulmonary metastasectomy. Two subgroups 
were identified: Resection of pulmonary metastases only (PM) and resection of hepatic and later 
pulmonary metastases (LPM). 
Results Patient characteristics were identical in both groups. Median follow-up in group PM was 35 
months and 38 months in group LPM. Two-year survival in group PM was 61%, in group LPM 81% 
(p=NS). Five-year survival was 30% and 20% in PM and LPM group respectively (p=NS). The median 
disease free survival was 12 months in the PM group and 13 months in LPM group.
The extent of pulmonary resection had no impact on survival. Complications occurred in 7 patients 
in PM group and 2 patients in LPM group. Complication rate and severity were related to the extent 
of pulmonary resection. A small group of patients underwent repeated pulmonary resection without 
serious complications. 
Conclusion Resection of pulmonary colorectal metastases may improve survival, even in patients who 
underwent hepatic resection for colorectal liver metastases at an earlier stage. 
Introduction
Colorectal carcinoma is a leading cause of cancer related mortality worldwide. Although primary 
resection of colorectal tumours is aiming for cure, about 40% of patients will eventually develop distant 
metastases. Most often the liver is the first site of metastatic occurrence. Next, pulmonary metastases 
are frequently observed and some patients may develop metastases in both liver and lung.
In several reports the feasibility of surgical treatment of colorectal liver metastases is already widely 
stated. Resection can be performed with acceptable morbidity and a 5-year survival rate between 
30% and 47% is reported 1-3. Also pulmonary metastasectomy has been proven to be a safe procedure 
with overall survival rates varying between 24% and even 72% 4-8. With ongoing surgical techniques 
and improved methods to detect metastases in an early stage, pulmonary metastasectomy becomes 
increasingly applicable in a growing group of patients. Even in patients that present with pulmonary 
metastases after hepatic metastasectomy, surgical therapy may be offered 9-21. Although in these 
patients there is clear evidence of systemic disease, local treatment of metastases may result in 
a beneficial effect on survival. Indications for pulmonary metastasectomy in these patients are, 
however, less defined and long term results may indeed be compromised compared to results obtained 
in patients without any history of hepatic metastatic disease. In the present study we evaluate the 
results of pulmonary resection of colorectal metastases in patients with or without a history of hepatic 
metastases. 
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Patients and methods
Study design
All records of patients undergoing pulmonary resection of colorectal metastasis from January 1997 
till December 2005 were evaluated. Within this group a subgroup of patients with previous hepatic 
metastasectomy was identified. 
Pulmonary resections were performed at the department of Surgery of Canisius Wilhelmina Hospital, 
Nijmegen, while hepatic resections were performed at the Surgical Oncology department of the 
University Medical Centre Nijmegen. Patients with either synchronous or metachronous colorectal 
metastases were included. Synchronous lesions were defined as metastases identified within six 
months of colorectal surgery.
Surgical procedures
Hepatic surgery was performed through an extended right subcostal incision. The abdominal 
cavity was explored thoroughly to exclude extrahepatic disease. Surgical treatment consisted of 
wedge resection or hemihepatectomy in all patients and in case of additional irresectable disease 
Radiofrequency Ablation (RFA) was performed. When resection was performed, a tumour free margin 
of at least 10 mm was aimed for. For local tumour ablation radiofrequency was performed. All ablative 
procedures were performed using an open surgical approach. During all ablative procedures, tumour 
destruction was directly monitored by ultrasound. Local tumour ablation was considered successful 
when all tumour tissue and a rim of normal tissue of about 1 cm was included in the treated area. 
Pulmonary metastasectomies were performed using unilateral or staged bilateral thoracotomy or 
videoscopic assisted thoracic surgery (VATS). If possible wedge resection was performed and only 
in case of multiple metastases confined in one lobe or central tumour localisation lobectomy or even 
pneumonectomy was indicated. 
Statistics
Follow up was performed using a standard protocol including total body CT scanning every 6 months. 
Survival curves were calculated using Kaplan-Meier estimates from the moment of pulmonary 
metastasectomy. For estimating differences between treatment groups chi-square test en student-t 
test were used.
Results
Patient characteristics
From January 1997 till December 2005 a total of 39 patients underwent pulmonary metastasectomy 
for colorectal metastases. In table 1 tumour and patient characteristics are listed differentiated for 
patients with (LPM) or without (PM) previous hepatic resection for metastatic disease. There were 
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no significant differences in patient characteristics between both groups nor in the time interval 
between resection of the primary tumour and the occurrence of lung metastases. This time interval 
was 29 months in the liver and lung resection group and 31 months in the lung resection only group. 
With regard to the TNM classification one patient presented with stage I disease, 15 with stage 
II, 13 with stage III and 10 patients with stage IV disease. The latter group consisted of 9 patients 
with synchronous liver metastases and one patient with synchronous lung metastases. Although 
the number of patients with synchronous disease was significantly higher in the group with liver 
and lung metastases, the number of patients with synchronous lung metastases in both groups was 
comparable. 
Table 1  Patient characteristics
Liver and lung metastasectomy Lung metastasectomy
Number of patients 21 18
Male : Female 8:13 11:7
Mean age (range, years) 62  (46-76) 63  (47-81)
Median number of lung lesions (range) 1  (1-6) 1  (1-3)
Stage primary tumour 
I
II
III
IV
0
7
5
9
1
8
8
1
Interval between colorectal resection 
and occurrence of pulmonary metastases 
(months median)
29 31
Interval between hepatic resection and 
lung resection (months median)
8
Median follow-up (range, months) 38  (2-68) 35 (0-100)
Type of pulmonary resection
In table 2 the types of pulmonary resections are listed. Most of the patients underwent unilateral 
posterolateral thoracotomy and wedge resection. A median of one pulmonary metastasis was treated 
in both groups. In the group treated for pulmonary metastases only, the number of lobectomies is 
evidently higher then in the group of patients undergoing pulmonary resection after former hepatic 
resection. An explanation could be that in the first years in this observational period surgeons were 
still convinced to perform more radical oncological surgery by performing lobectomies in patients 
without a history of hepatic metastases. In the last years of this observational period wedge resections 
were always the operations of choice if possible. 
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Table 2  Type of thoracotomy and pulmonary resection.
Lung and liver metastasectomy Lung metastasectomy
Surgical approach
VATS
Unilateral thoracotomy
Bilateral thoracotomy
 
3
16
2
21
 
2
15
1
18
Pulmonary resection
Wedge resection
Lobectomy
Pneumonectomy
 
20
1
0
21
 
9
8
1
18
Overall survival
At the end of follow-up 8 patients in the LPM group and 6 patients in the PM group were still alive. 
Median survival, as determined from the time of pulmonary resection, was 38 months in the group with 
former hepatic resection compared to 35 months in the group with pulmonary resection only. Two year 
survival was 81% in the LPM group and 61% in the PM group (Figure 1). Five year survival was 20% and 
30% respectively. Differences in survival between both groups were not statistically different. 
Disease free survival
Median disease free survival in the pulmonary resection group only was 12 months and 13 months in 
the group with pulmonary resection and former hepatic resection (figure 2). In the group pulmonary 
metastasectomy only, 8 patients developed new pulmonary metastases of which 7 patients underwent 
a second pulmonary resection. Two patients even underwent a third metastasectomy. All of the 
patients undergoing secondary pulmonary surgery eventually developed extrapulmonary disease.
Figure 1  Overall survival (LPM: liver and pulmonary metastasectomy, PM: pulmonary metastasectomy)
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In the group of liver and lung metastasectomy 12 patients presented with new pulmonary metastases 
during follow up. Only five of them underwent a second pulmonary metastasectomy. Of these five 
patients three persons eventually developed extrapulmonary disease.
Figure 2  Disease Free Survival (LPM: liver and pulmonary metastasectomy, PM: pulmonary metastasectomy)
Complications
In the group with more extensive pulmonary resection, one patient died postoperatively, after 
pneumonectomy, due to severe cardiac failure. Three other patients developed cardiac failure 
postoperatively. Two patients had prolonged air leakage. All these complications occurred in patients 
undergoing lobectomies. In patients treated with wedge resection one patient developed pulmonary 
infection. Other complications noticed after this type of pulmonary metastasectomy are wound 
infection in one patient and epidural abscess leading to surgery and temporary pareses in another 
patient probably due to epidural anaesthesia.
Discussion 
The most common sites of metastatic disease from colorectal cancer are liver and lungs. Although 
chemotherapeutic regimens have offered significant improvements in overall survival, surgical 
resection still remains the best curative option for colorectal metastatic disease 22,23. Many reports show 
safety and survival benefits for surgical treatment of colorectal liver metastases 1-3. Also in patients 
with pulmonary metastases survival is improved by surgical resection at acceptable complication rates 
4-8. It is still an unresolved issue, however, whether resection of pulmonary metastases after previous 
hepatic metastatic surgery will also lead to an identical survival benefit, although some earlier studies 
do report very acceptable survival rates 9-21. 
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Comparison of survival and influencing factors
In our files 39 patients were identified as undergoing pulmonary resection of colorectal metastases. 
Of these patients 21 underwent hepatic resection of metastatic disease in an earlier phase while 18 
patients underwent lung resection only. Overall survival and disease free survival were comparable 
for both groups with 5 year overall survival rates of 20 and 30% respectively. In literature comparable 
figures are mentioned after combined resections, although some series even describe 5 year survival 
rates up to 73% 9. 
In most studies survival rates after resection of synchroneous liver and lung metastases is worst when 
compared to lung metastases occurring after the initial liver resection 12,19. In our group only one patient 
had simultaneous liver and lung metastases. Remarkebly this patient is still alive after 5 years without 
evidence of disease. Other negative predictors of survival mentioned in literature are severly elevated 
pre-operative CEA level, number of pulmonary metastases and non tumour free resection margins 4,7,8.
Disease free survival is 12 months in the lung only group and 13 months in patients treated for lung 
and liver metastases. Only a small number of patients will remain without evidence of disease. Repeat 
resections may be offered to these patients. It is remarkable that we observed more repeat resections 
in the PM group than in the LPM group. Probably repeat thoracotomy is considered a bridge too far 
in the minds of most patients (and maybe also professionals) in the LPM group, although survival 
differences between both groups do not support this. 
Complications and relation with type of resection
Although all studies on patients with resection of pulmonary and/or hepatic colorectal liver 
metastases are retrospective and figures are based on selected patients, most series suggest a clear 
benefitial effect when compared to systemic chemotherapy. Moreover, these results are achieved at 
the costs of only a limited complication rate. Also our data show an acceptable complication rate after 
pulmonary surgery. In 39 patients one postoperative death occurred. It concerned a dramatic cardiac 
failure after pneumonectomy leading to death in a patient with history of cardiac problems. Most 
complications were seen in patients undergoing more complex pulmonary resections i.e. lobectomy/
pneumonectomy. After wedge resection the only complications notified were wound infection and 
epidural abscess in one patient. It is preferable in patients with pulmonary metastases to choose the 
least invasive procedure of resection. Wedge resections leads to less complications postoperatively, 
more remaining pulmonary tissue and gives the same survival benefits as more extensive pulmonary 
resections 24. However, others report higher incidence of local recurrence and worse survival rates 
when comparing wedge resection with anatomical resection 5. 
Future considerations
It would be preferable to be able to identify patients most likely to benefit from surgery for metastastic 
disease. Today imaging studies, like FDG-PET scanning, confirming the presence or absence of other 
(distant) metastases, are more widely available and will be more and more part of the pre-operative 
work up of patients eligible for metastasis surgery 25,26. 
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Certainly with ongoing techniques of in situ local tumour ablation such as RFA also patients unfit to 
undergo thoracotomy or laparotomy can be candidate for pulmonary and hepatic ”metastasectomy” 
27-33. Main advantage of these techniques are that they are much less invasive especially when 
performed percutaneously, can be done sometimes using local anesthesia and are easy to repeat in 
case of recurrent metastatic disease. Especially in patients who have residual disease or recurrence of 
pulmonary and/or liver metastases local ablative techniques offer an attractive alternative treatment 
option. 
Conclusion
We can state that resection of pulmonary metastases after former hepatic resection is safe and results 
in an overall survival benefit identical to resection of pulmonary lesions in patients without preceding 
metastatic disease. 
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Abstract
Background Cryoablation has been used successfully for the local treatment of several cancers. 
Besides local destruction, a systemic anti-tumor response has been postulated after cryoablation 
of tumor tissue. In this study we evaluate the possible systemic anti-tumor response induced by 
cryodestruction of tumor tissue in two mouse tumor models.
Methods Mice received two subcutaneously placed tumor implants (thigh and flank) of the non-
immunogenic mouse colon tumor cell line, colon 26-B. After 7 days, the thigh implant was treated 
by cryoablation or excision and the effect on secondary tumor growth was determined by volume 
measurement of the non-treated flank tumor. Cytokine (IL-1α and TNF-α) levels in plasma were 
measured after treatment.
Similar experiments were performed in nude mice using a human melanoma cell line (MV3). 
Moreover, in this model the effect of cryoablation on development of spontaneous lung metastases 
was evaluated.
Results In the colon 26-B tumor model treatment of primary tumor implants by cryoablation resulted 
in a significant inhibition of secondary tumor growth compared to animals treated by surgical excision 
(p<0.01). Six hours after treatment, plasma levels of IL-1α and TNF-α were higher after cryoablation 
than after excision (p<0.01). 
Also in the nude mice model cryoablation resulted in inhibition of secondary tumor growth, though 
not significant. Mice treated by cryoablation showed significantly less lung metastases compared to 
those treated by excision (p=0.03). 
Conclusions Cryoablation of tumor tissue can result in inhibition of secondary and metastatic tumor 
growth. A cytokine response induced by cryoablation of tumor tissue may attribute to this feature. 
Introduction
Cryoablation, or destruction of tissue by freezing, has long been recognized as a potential tool in 
the treatment of cancer 13. The technique has extensively been used for the treatment of various 
tumors at superficial anatomic sites such as skin, oral cavity, and head/neck region. More recently, 
new technical developments in cryosurgical equipment and ultrasound devices made it possible to 
apply cryoablation also for the treatment of bone tumors, prostate cancer and liver tumors.
It has been demonstrated that the induction of a freeze-thaw process by cryoablation can result in 
effective tumor destruction in situ 2,9,18,24. 
Besides local destruction of the primary tumor, it has been claimed that cryoablation is able to induce 
a more or less systemic anti-tumor immune response. Several case reports mention the reduction of 
metastatic disease after cryoablation of the primary tumor 1,29.
In the early years of cryoablation, the immune modulating effect of cryoablation was evaluated in 
several animal models 3,6,10,11,14,16,20,21,26,27,28,32. Both tumor suppressor and tumor enhancing effects were 
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noticed, without exclusive data on the precise underlying mechanisms. Different immune responses 
elicited by tumor antigens released after tumor cryoablation were generally felt responsible for some 
of the contrasting results. Besides, most of these studies were performed in highly immunogenic tumor 
models that are less relevant in human tumor immunology. With recent advances in cryosurgery and 
the application of the technique for the treatment of a wider range of malignant tumors, the interest 
in its systemic effects revives. If indeed cryoablation of tumor tissue is able to initiate a systemic 
anti-tumor response, this phenomenon could be of potential benefit in the treatment of (micro-) 
metastastic disease. Especially, since nowadays enhancement of a systemic anti-tumor response with 
immunotherapy is within reach. 
This study is designed to examine the effect of cryoablation on secondary tumor growth. For this 
purpose a two-tumor model was designed with a non-immunogenic mouse colon tumor, colon 26-B. 
Moreover, the effect of cryoablation was investigated in a spontaneous metastasizing tumor model 
(MV3) in athymic nude mice.
Materials and methods
Mice
Normal male BALB/c mice, 6 to 8 weeks old were obtained from Charles River (Sulzfeld, Germany) and 
were kept at the Central Animal Laboratory in Nijmegen, the Netherlands, under specified pathogen 
free conditions. The mice were housed 5-10 per cage, in a 12:12 hour light:dark cycle environment, with 
ad libitum access to food and water.
BALB/c athymic nude mice, 6 to 8 weeks old, were obtained from the nude mice facility of the Central 
Animal Laboratory, University of Nijmegen.
Experimental protocols were all reviewed and approved by the Animal Experimental Committee of 
the University of Nijmegen.
Tumors
The colon 26-B tumor was acquired with kind permission of Dr. Y. Kamm (Medical Oncology Department, 
University Hospital Nijmegen) and is a derived from the colon 26 cell line, as originally described by 
Corbett et al. 8. Tumor fragments of colon 26-B tumor were kept in store in liquid nitrogen. At start 
of the experimental protocols, fragments were thawed and implanted subcutaneously into the right 
flank. Further, the tumor was maintained in passage by subsequent subcutaneous transplantation of 
tumor tissue fragments every 2-3 weeks.
The MV3 tumor cell line was derived from a human melanoma metastasis 31. First passage tumors were 
induced by inoculation of 1x106 MV 3 cells in the right flank of nude BALB/c mice. Further passages were 
done by subcutaneous transplantation as with colon 26-B tumor. From day 7, tumor growth was followed 
by measurement of three orthogonal diameters using a slide caliper. By using the following formula the 
tumor volume (TV) was estimated: TV = X x Y x Z x 0.5 (x=length, y=height, z=width) 22.
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To test immunogenicity of the colon 26-B cell line rechallenge experiments were performed. The 
primary tumor was resected and secondary inoculation with the same cell line followed after one 
week. None of the rechallenged mice showed any rejection or growth inhibition of this secondary 
tumor implant.
Tumor transplantation
For both, colon 26-B and MV3 tumor cell lines, the same transplantation protocol was used. On 
day 0 a tumor-bearing mouse was sacrificed and tumor tissue was harvested under semi-sterile 
conditions. The tumor was minced and tissue fragments with a diameter of 2-3 mm were implanted 
subcutaneously into the right hind thigh. The same inoculation procedure was carried out on day 3 
when a tumor fragment was transplanted into the right flank. During transplantation diethyl ether 
anesthesia was used. Take rate after inoculation of the colon 26-B tumor and MV3 tumor was up to 
100%. Both tumor cell lines showed fast growing tumors in vivo.
The colon 26-B cell line has only weak metastatic potential. When left untreated animals generally 
die within three weeks from cachexia due to progressive local tumor growth. The MV3 cell line is a 
strongly metastasizing cell line, exclusively resulting in lung metastases 31.
Surgical procedures
At day seven treatment protocols were carried out. Cryosurgery was performed using the CS-76 
cryosurgical system (Frigitronics, Inc., Shelton, CT). Pressurized liquid nitrogen was applied to the tumor 
through the intact overlying skin using a 2-mm probe. A three-cycle freeze-thaw regimen was performed 
to ensure maximum tumor cell death. In control experiments normal skin and muscle of the non-tumor 
bearing left thigh were frozen to compare the effect of freezing normal and tumor tissue.
Excisional treatment of the tumor consisted of complete removal of the tumor with overlying skin 
and part of the underlying muscle. 
All treated animals underwent general anesthesia using a hypnorm/midazolam/water suspension 
injected intraperitoneally in a volume of 0.1 ml.
Histology
On days 1, 3 and 14 after treatment tumors of the thigh and flank were harvested for histopathological 
examination. Tumor tissue was fixed in 4% buffered formalin and embedded in paraffin for 
haematoxylin-eosin (H&E) staining. 
For the detection of lung metastases in nude mice, lungs were excised 35 days after the start of the 
protocol, formalin fixed and embedded in paraffin for H&E staining. Two cross sections of each lung 
were examined for the presence of lung metastases.
IL-1 and TNF assay
After treatment of the tumor in the thigh blood was collected at two time points post-therapy. Six and 
48 hours after surgery mice were anesthetized with diethyl ether and blood was collected in EDTA-
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plasma tubes by means of eye extraction. After centrifugation at 1500 g plasma was stored at -80°C 
until assayed. IL-1α and TNF-α were measured by Radio Immuno-absorbent Assay (RIA) 17. Detection 
levels of IL-1α and TNF-α were 0.02 and 0.04 ng/ml respectively.
Statistical analysis
Statistical analysis of differences in tumor volume and cytokine levels in plasma was accomplished 
with Student’s t-test. For difference in presence of lung metastases Fisher’s exact test was used. 
Statistical significance was assumed when P < 0.05.
Results
Local efficacy of cryoablation
On day 7 after tumor inoculation in the thigh, colon 26-B and MV3 tumors were treated either by 
cryoablation or excision. At that stage the tumor in the thigh had reached a volume of approximately 
60 mm3 with a diameter of about 6 mm. After cryoablation of the tumor a darkish green scar developed 
within few hours after treatment. This scar developed into a dry black crust in two or three days. 
Local efficacy of cryoablation was evaluated by histopathological examination of the treated areas at 
definite days after cryoablation. For this purpose, groups of 7 animals were sacrificed on day 1, 3 and 
14 after cryoablation. In addition, efficacy of local treatment was judged by the occurrence of local 
recurrence during all further experiments described in the study.
At day 1 after cryoablation histopathological evaluation by H&E staining showed picnotic cores in 
tumor cells and surrounding tissue, with slight infiltration and edema. After 72 hours the infiltrate and 
edema had increased and tumor cells showed a more progressed pattern of necrotic disintegration. 
After two weeks there were no signs of vital tumor cells and most necrotic tumor tissue was resolved 
leaving the sight is of some fibrosis with infiltrating cells.
In all experiments (colon 26-B and MV3) performed in this study, local recurrence after cryoablation 
was observed in only 6% of the mice. This result was comparable to the number of recurrences (8%) 
observed after excision of the tumor. 
Effect of cryoablation on secondary tumor growth in the colon 26-B tumor model
The effect of cryoablation of the primary tumor on the growth rate of the second tumor in the flank 
was determined and compared to excisional treatment. Growth curves of the tumor in the flank, after 
treatment of the primary tumor in the thigh, are given in figure 1. Cryoablation of the primary tumor 
resulted in a significant growth inhibition of the secondary tumor compared to excision. This difference 
in growth rate of the secondary tumor after cryoablation and excision was significant from the first 
postoperative day (p < 0. 01). To investigate whether the difference in secondary tumor growth after 
cryoablation and excision was due to cryoablation of tumor tissue or to cryo treatment itself, animals 
underwent cryotreatment of skin and muscle of the non-tumor bearing left thigh. For comparison 
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of results any effect of the primary tumor on secondary tumor growth was ruled out by excision of 
the primary tumor on the right thigh. Results shown in figure 2 demonstrate that cryotreatment of 
normal tissue did not influence the growth rate of the secondary tumor. Comparable growth curves 
were observed for mice treated by excision of the thigh tumor and mice treated by excision of the 
thigh tumor plus cryotreatment of the healthy thigh. In contrast, cryoablation of tumor tissue resulted 
again in a significant inhibition of secondary tumor growth. 
Histological evaluation by means of H&E staining showed no significant differences between flank 
tumors of animals treated by cryoablation or excision. Great histological differences between tumors 
of animals within one treatment group made it impossible to obtain clear differences between 
excisional or cryoablative treatment. 
Effect of cryoablation on secondary tumor growth in nude mice
To determine whether the observed difference in growth rate after cryoablation and excision could be 
due to T cell specific immune induction after cryoablation of tumor tissue similar experiments were 
performed in nude mice. For this purpose nude mice were inoculated with the human melanoma 
cell line, MV3. The protocol was identical to that of the colon 26-B experiments. As shown in Figure 
3, tumor growth after cryoablation was slower than after excision, although this difference was not 
statistically significant. 
To examine the effect of cryoablation on the development of spontaneous metastases, tumor tissue 
of the highly metastatic MV3 cell line was implanted into the thigh and flank. In untreated mice 
microscopic examination of the lungs revealed metastatic lesions in 6 out of 7 mice (Table 1). Excision 
of the primary tumor had no effect on the frequency of metastases; 8 out of 10 mice showed lung 
metastases after excision. In contrast, only 3 out of 11 mice treated by cryoablation showed lung 
metastases. Moreover, the metastatic lesions detected after cryoablation were significantly smaller 
compared to the lesions in lungs of the untreated mice and mice treated by excision.
Table 1  Development of lung metastases in the MV3 tumor model in nude mice. Mice received subcutaneous 
tumors on day 0 an day 3. Treatment of the thigh tumor followed on day 7. Mice were sacrificed for observation 
of lung metastases at day 35 (* p=0.03, Fisher’s exact test).
No treatment
Cryoablation 
thigh tumor
Excision thigh 
tumor
No. mice showing metastases/ total no. of mice. 6/7 3/11 * 8/10 *
Relative mean size of metastases Large Small Medium
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Figure 1  Growth of flank tumors in the colon 26-B model after treatment of the thigh tumor. (p< 0.01 statistical 
difference between animals treated by cryoablation and excision, Student-t test).
Figure 2  Growth curves of flank tumors in the colon 26 B tumor model. (x = p<0.05 and xx = p< 0.01, Statistical 
difference between animals treated by cryoablation and excision or excision+cryoablation of normal tissue, 
Student-t test).
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Figure 3  Growth curves of flank tumors in the MV3 tumor model after treatment of the thigh tumor. No 
statistical difference in tumor growth was noted.
Plasma cytokine levels after treatment of the colon 26-B tumor
Six and 48 hours after treatment blood samples of individual mice were examined for circulating 
IL-1α and TNF-α (table 2). Blood samples of colon 26-B tumor bearing mice with no treatment did 
not show any detectable levels of TNF-α and IL-1α levels (data not shown). Within six hours after 
cryoablation both IL-1α and TNF-α levels were elevated when compared to plasma levels of animals 
that underwent excision of the limb tumor (p<0.01). Two days after treatment plasma levels of both 
cytokines have normalized again with no differences between cryoablation and excision groups.
Table 2  IL-1α and TNF-α levels in plasma of mice, 6 and 48 after treatment of the colon 26-B thigh tumor (ng/ml, 
n=5). * P<0.01 (Student-t test).
6 hours after treatment 48 hours after treatment
IL-1α TNF-α IL-1α TNF-α
Cryoablation 0.06 * 0.09 * 0.03 0
Excision 0.03 * 0 * 0.03 0
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Discussion
The local effectiveness of cryosurgery in the treatment of malignant tissue has already been 
established in several experimental and clinical studies 2,9,16,18,23,24. Also this study leaves no doubt on 
the effectiveness of cryosurgery in the treatment of the primary tumor. When compared to surgical 
excision a recurrence rate of approximately 7% was observed in both groups. 
For evaluating the effect of cryosurgery on distant tumor, two different models were used. In the 
colon 26-B tumor model it was demonstrated that cryoablation of tumor tissue has a significant 
inhibitory effect on secondary tumor growth. Compared to excision, cryoablation of a primary 
tumor in the thigh clearly inhibited tumor growth of a secondary tumor in the flank. This effect on 
secondary tumor growth was most evident during the first days after treatment and was specifically 
related to the destruction of tumor tissue. Cryotherapy of normal tissue did not result in any growth 
inhibition of secondary tumor. T cell mediated immunity, however, seemed not directly involved in 
the phenomenon observed. In nude mice cryoablation of the primary tumor resulted in inhibition 
of the outgrowth of lung metastases. Miya et al. described a more cell-mediated immunity after 
cryoablation of experimental tumors 19. In this study a relative immunosuppressive effect three weeks 
after cryosurgery is followed by increased anti-tumor immunity after 6 weeks. Our model focuses 
on the early events after cryosurgery and rapid tumor growth of the colon 26-B tumor makes it 
impossible to evaluate the immune response after more than three weeks. Though our results point 
at a rapid and therefore probably cytokine mediated response, a T cell response after cryosurgery can 
not be excluded and insight in this immunological response may provide potential tools to enhance 
immunostimulation and prevent immunosuppressive effects after cryoablation.
In this study the process of cryosurgery was performed in the same way as in clinical practice for liver 
malignancies. In order to boost an immunological response, repeated freezings, a few days or weeks 
after the first cryotreatment have been described 12,29,33. Although, the concept of repetitive booster 
freezings could be of potential value in the treatment of hepatic malignancies, repeated freezings by 
means of open intra-abdominal surgery will certainly imply practical operative problems and risks. 
After cryoablation of tumor tissue increased levels of IL-1α and TNF-α were measured. This cytokine 
response after cryoablation of tumor tissue could probably play part in the mechanism responsible 
for the inhibition of secondary tumor growth. 
Our findings are in agreement with earlier reports 6,11,21. Also in these studies a systemic anti-tumor 
response after cryoablation was observed as cryoablation of a primary tumor resulted in failure of 
tumor growth after rechallenge. Most of these studies were performed in highly immunogenic tumor 
models. In these models secondary tumor implants after removal of the primary are spontaneously 
rejected or show decelerated growth. For clinical perspective it should be more promising to attain 
such a systemic anti-tumor response in a non-immunogenic tumor model. In this study we therefore 
used the syngeneic non-immunogenic colon 26-B tumor cell line. In several rechallenge experiments 
this tumor cell line did not show any rejection or growth retardation of a secondary tumor implant 
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(data not shown). These results demonstrate that also in non-immunogeneic tumors cryoablation of 
tumor tissue can result in a systemic anti-tumor response. 
The nature of this response is not clear. It has been assumed that antigen release from necrotic tumor 
tissue could play a role in the induction of a specific or aspecific anti-tumor response. Early reports on 
the effect of in situ cryoablation already stated elevated tumor antigen levels in serum 20,28. Indication 
for a specific anti-tumor response came from rechallenge studies demonstrating only anti tumor 
immunity against tumor tissue identical to cryotreated tumor tissue. Specific T cell mediated immune 
responses after cryoablation were generally held responsible for this phenomenon 3. However, also 
aspecific immune responses have been described such as an increased activity of natural killer cells 
and macrophages or increased production of cytokines after cryoablation 4,5.
The fact that in our study tumor growth inhibition was observed immediately after cryotherapy 
suggests that in this model, using a non-immunogeneic tumor, a T cell dependent anti-tumor 
response is less likely. Also the experiments performed in nude mice, in which cryotherapy inhibited 
the development of lung metastases, indicate a non T cell dependent mechanism. Immediately after 
cryotherapy we observed an emergence in levels of circulating IL-1α and TNF-α. Tumor regression 
by TNF-α has extensively been described, especially in combination with other cytokines like IFN-γ 
7,15,25,30. The induction of a cytokine response after cryoablation, as observed in our experiments, may 
play a role in tumor growth inhibition of the secondary tumor. Such mechanism would also explain 
the results in nude mice, since also nude mice are capable to produce cytokine responses. Our results 
do not exclude any T cell involvement, but give more reason to attribute early tumor growth inhibition 
to less specific responses such as cytokine release. 
Within this tumor model we were unable to obtain a histological substrate for the difference in tumor 
growth of flank tumors between animals treated by cryoablation or excision. This was due to great 
histological variety between tumors of identically treated animals. 
In conclusion, this study shows that cryoablation is an effective local treatment for solid tumors. Next 
to its local destructive effect cryosurgery leads to an inhibition of secondary and metastatic tumor 
growth as compared to surgical excision. With regard to possible clinical application, these findings 
give reason to further explore the mechanisms behind this growth inhibitory effect and to investigate 
whether further immune modulating strategies can enhance the systemic anti-tumor response.
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Abstract
Introduction	Earlier reports on animal studies showed inhibition of secondary tumor growth and 
metastases after cryoablation, probably mediated by an inflammatory response. In this study 
enhancement of this inflammatory response and its possible additive anti-tumor effect is evaluated 
in a mouse tumor model.
Materials	and	methods	Mice received two subcutaneously implanted C-26B tumors on respectively 
day 0 (thigh) and day 7 (flank). The thigh tumor was treated by either cryoablation or resection. In 
addition animals received a single dose of lipopolysaccharide (LPS) or anti-IL10 together with or two 
days after surgical treatment. Growth of flank tumor was followed and plasma levels of IL-1α and 
TNF-α were measured.
Results	Compared to excision of the primary tumor cryosurgery clearly induced inhibition of secondary 
tumor growth while plasma levels of TNF (0.09) and IL-1 (0.06) were significantly elevated after 
cryosurgery when compared to excision (TNF 0.0, IL-1 0.03; p<0.01). Administration of LPS two days 
after cryosurgery did not lead to extra inhibition of secondary tumor growth, even at high doses. 
Remarkably, dose response studies with LPS administered two days after treatment showed a high 
mortality at a dose of 200 µg (75%) in the excision group while mortality in the cryo treated group 
was 13% (p<0.02). Mortality was directly related to cytokine levels that were significantly higher in 
the excision group (TNF 3.60, IL-1 0.30) when compared to the cryo treated group (TNF 1.0, IL-1 0.15; 
p<0.01). In contrast, when 25 µg LPS was given at the same time with treatment of the primary tumor 
either by cryosurgery or excision, mortality in the cryo treated group (85%) was higher than in the 
excision group (14%, p<0.05). Again mortality was related to post treatment cytokine levels which now 
were significantly higher in the cryo treated animals (TNF 1.30, IL-1 0.35) than in animals treated by 
excision (TNF 0.60, IL-1 0.10; p<0.01). Administration of anti-IL-10 did not lead to extra tumor growth 
inhibition.
Conclusion	 These experiments confirm the hypothesis that cryosurgery leads to a systemic 
inflammatory response. This reaction can lead to inhibition of tumor growth. Administration of LPS 
after cryosurgery does not lead to an extra anti-tumor response, animals appear to become endotoxin 
tolerant. Adversely, when LPS is administered together with cryosurgery animals are extremely 
sensitive for LPS. These findings are in accordance with the clinical observation of cryoshock after 
cryoablation of liver metastases.
Introduction
The destruction of tissue by freezing, cryoablation, has been used for many years in the treatment of 
different types of cancers of skin, liver, prostate and rectum 1-7. 
In the early years of cryosurgery several clinical observations showed reduction of pulmonary 
metastases after cryosurgical ablation of primary prostate tumor 8,9.
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The possible immune modulating effects of cryosurgery were studied in different tumor models. In 
a rat carcinoma tumor model a reduction in metastatic tumor growth after cryosurgery resulted in 
prolonged survival as compared to animals treated by excision 10. Comparable results with a reduction of 
secondary and metastatic tumor growth were observed in a rat sarcoma tumor model 11. The induction 
of a tumor specific immune response by elevated lymphocyte mediated toxicity was postulated as 
a possible explanation for the anti-tumor response observed 12-15. Other studies, however, could not 
confirm an inhibitory response after cryosurgery or even showed an enhancing effect on tumor 
growth 16-20. Due to these contrary and non-conclusive results the interest in cryosurgical research 
diminished for several years. However, with recent advances in the technique of cryosurgery and with 
the introduction of other in situ ablative techniques like radiofrequency therapy, there is a renewed 
interest in local destructive tumor treatment and the possible systemic anti-tumor effects that can 
be obtained. Moreover, with the increasing possibilities of immunotherapy a possible enhancement 
of the immune response after local tumor treatment could be induced in order to suppress micro-
metastatic systemic disease. 
In an earlier report we mentioned the inhibitory effect of cryoablation of a primary tumor on the growth 
of secondary tumor and metastases, when compared to treatment by surgical excision 21. This anti-tumor 
effect could be partly attributed to a generalized inflammatory response after cryoablation as seen by 
increased levels of cytokines. In the present study we try to further identify this anti-tumor response 
in a non-immunogenic mouse tumor model and investigate whether this potential systemic anti-tumor 
response after cryoablation can be enhanced through administration of LPS and anti-IL-10. 
Materials and methods
Animals
Male BALB/c mice, 6 to 8 weeks old were obtained from Charles River (Sulzfeld, Germany) and were 
kept at the Central Animal Laboratory in Nijmegen under specified pathogen free conditions. The 
mice were housed 5-10 a cage, in a 12:12 hour light:dark cycle environment, with ad libitum access to 
food and water.
Experimental protocols were all reviewed and approved by the Animal Experimental Committee of 
the University of Nijmegen.
Tumors
Fragments of colon 26-B tumor (originally described by Corbett 22), were stored in liquid nitrogen. At 
start of the experimental protocols, tumor fragments were thawed and implanted subcutaneously 
into the right flank. From day 7, tumor growth was followed by measurement of three orthogonal 
diameters using a slide caliper. With use of the following formula the tumor volume (TV) was 
calculated: TV = X x Y x Z x 0.5 (x=lenght, y=hight, z=widht) 23.
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To test immunogenicity of the colon 26B tumor cell line rechallenge experiments were performed. The 
primary tumor was resected and secondary tumor implantation with the same cell line was performed 
after two weeks. None of the rechallenged mice showed any rejection or growth inhibition of this 
secondary tumor implant.
Tumor transplantation
A tumor-bearing mouse was sacrificed and tumor tissue was harvested under semi-sterile conditions. 
Tumor tissue fragments of 2-3 mm diameter were implanted subcutaneously into the right hind thigh 
on day 0. On day 3 a similar procedure was carried out for implanting a tumor fragment into the right 
flank. Diethyl ether anesthesia was used during implantation. After inoculation of the colon 26-B 
tumor the tumor take rate was up to 100%. 
Surgical procedures
At day seven surgical treatment protocols were carried out. Cryosurgery of the thigh tumor was 
performed using the CS-76 cryosurgical system (Frigitronics, Inc., Shelton, CT). Pressurized liquid 
nitrogen was applied to the tumor through the intact overlying skin using a 2-mm probe. A three-
cycle freeze-thaw regimen was performed to ensure maximum tumor cell death. In case animals 
were treated by excision of the thigh tumor, this was performed by complete removal of the tumor 
with overlying skin and part of the underlying muscle. Recurrence rates of the primary tumor after 
cryoablation or excision were comparable, respectively 8 and 7%.
All operations were performed under general anesthesia using a 0.1 ml hypnorm/midazolam/water 
suspension injected intraperitoneally. 
LPS administration
Lipopolysaccharide from Serratia marcescens (Sigma, The Netherlands) was used to provoke an 
acute inflammatory response. At several time points in the experimental protocol LPS was injected 
intraveneously into the retro-orbital plexus under slight diethyl ether anesthesia.
Anti-IL-10 administration
Anti-IL-10 (JES5-2A5), at a dose of 10 mg was administered intraperitoneally. The antibody was injected 
at day 7 of the experimental protocol at the time of the surgical procedure. 
IL-1 and TNF assay
After treatment of the tumor in the thigh, blood was collected at two time points post-therapy. Six 
and 48 hours after surgery (with or without LPS administration) mice were anesthetized with diethyl 
ether and blood was collected by eye extraction in an EDTA-plasma tube. After centrifugation at a 
rate of 3000 rpm plasma was stored at -80°C until assayed. IL-1α and TNF-α were measured by Radio 
Immuno-absorbent Assay (RIA) 24. Detection levels of IL-1α and TNF-α were 0.02 and 0.04 ng/ml 
respectively. 
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Statistical analysis
Analysis of tumor volumes and plasma cytokine levels was accomplished with Students t-test. For 
difference in mortality Fisher’s exact test was used. Statistical significance was assumed when p < 0.05.
Results
Treatment of primary tumor (thigh) and the effect on secondary tumor growth
Figure 1 shows growth rates of the secondary tumor of four experimental groups treated either by 
cryoablation or excision, with or without LPS administration. Cryoablation of the primary tumor 
(thigh tumor) resulted in a significant growth inhibition of the flank tumor as compared to animals 
treated by surgical excision (p < 0.01). In order to prolong the anti-tumor effect of cryoablation 50 
µg of LPS was administered intraveneously two days after initial treatment of the primary tumor. In 
animals treated by cryosurgery LPS injection did not lead to extra growth inhibition of tumor in the 
flank. On the contrary, in animals treated by excision, LPS administration resulted in a significant 
inhibition of flank tumor growth (p<0.01).
Figure 1  Growth curves of flank tumors after treatment of the thigh tumor with or without administration of 50 mg 
of LPS at day 9 (n=10 animals per group).
The effect of dose and time modifications of LPS administration
Dose: After initial experiments with administration of 50 µg of LPS further experiments were 
performed using higher doses of LPS. LPS at doses of 200 and 500 µg was administered 2 days after 
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surgical treatment of the primary tumor (day 9). In animals treated by cryosurgery higher doses of 
LPS did not lead to significant extra tumor growth inhibition. In animals treated by excision of the 
primary tumor and high doses of LPS the effect of LPS on secondary tumor growth, as observed at low 
dose, could no longer be demonstrated because doses of 200 and 500 µg resulted in a high mortality 
rate. In this regard a remarkable difference was observed between animals treated by cryosurgery 
and those treated by excision. Table 1 shows mortality rates after different doses of LPS two days after 
treatment. Significant differences in mortality occurred between animals treated by cryosurgery and 
those treated by excision (p < 0.05).
Time of administration: A series of experiments was performed in which LPS was administered at 
the time of cryosurgery or excision of the primary tumor (day 7). In animals treated by cryosurgery 
as well as in animals treated by excision there was no significant difference in flank tumor growth 
with or without additional LPS injections. Though again a significant difference in mortality occurred 
between animals treated by cryosurgery and those treated by excision (table 2). In contrast to the dose 
escalating studies in which LPS was administered two days after surgical treatment and that mainly 
showed mortality in animals treated by excision, LPS injection at the time of treatment resulted in a 
high mortality in the group treated by cryosurgery while the same high doses of LPS were hardly toxic 
to animals treated by excision (p<0.05). 
Table 1  Mortality after LPS administration 48 hours after treatment of the thigh tumor.
    50 μg LPS 200 μg LPS 500 μg LPS
Cryoablation 0/8 1/8* 4/8
Excision 1/8 6/8* 4/4
deaths/total number of animals, * p< 0.05 
Table 2  Mortality after LPS administration at the time of treatment of the thigh tumor.
  0.1 μg LPS 1.0 μg LPS 25 μg LPS
Cryoablation 0/5 4/5* 6/7*
Excision 0/7 0/7* 1/7*
deaths/total number of animals, * p< 0.05 
Plasma cytokine levels after surgical treatment and LPS administration
In order to evaluate the inflammatory response, cytokines IL-1α and TNF-α were measured in plasma 
of different groups of treated animals (table 3). A significant elevation in plasma IL-1α and TNF-α 
was seen 6 hours after cryosurgical treatment. Two days after treatment plasma cytokine levels have 
normalized again (data not shown). In contrast to cryosurgery, excision of the primary tumor did not 
result in a significant elevation of IL-1α and TNF-α in the plasma. In animals that also received LPS 
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directly after surgical treatment (day 7) a significant increase in cytokine plasma levels was observed. 
This increase was significantly higher in animals treated by cryosurgery plus LPS than in those treated 
by excision plus LPS (p<0.01). 
When LPS was administered two days after treatment this effect was reversed and cytokine response 
was significantly higher in animals that had been treated by excision (p< 0.01). 
Table 3  Plasma IL-1 and TNF levels after treatment of the thigh tumor with or without lLPS administration.
Treatment day 7 Treatment and LPS day 7 Treatment day 7 and LPS day 9
IL-1α TNF- α IL-1α TNF- α IL-1α TNF-α
Cryoablation 0.06* 0.09* 0.35* 1.30* 0.15* 1.0*
Excision 0.03* 0.00* 0.10* 0.60* 0.30* 3.6*
n=10 animals per group, * p< 0.01
Effect of anti-IL-10 administration on secondary tumor growth
Since cryosurgery seems to be associated with an acute inflammatory response, blocking of the 
anti-inflammatory cytokine IL-10 could possibly induce an extra anti-tumor effect. Figure 2 shows 
Figure 2  Growth curves of flank tumors after treatment of the thigh tumor with or without administration of 
anti-IL-10 intraperitoneally (n=10 animals per group).
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growth curves of groups of animals treated by either cryosurgery or excision, with or without 
intraperitoneally injection of 10 mg of anti-IL10. As in earlier experiments growth curves of animals 
treated by cryosurgery are significantly different from those of animals treated by excision. However, 
administration of anti-IL-10 does not significantly alter the growth of secondary tumor, neither in the 
cryosurgical nor the excisional treated group.
Discussion
Initial experiments in this study show a relative inhibition of secondary tumor growth after cryosurgery 
when compared to animals treated by excision of the primary tumor. In the first hours after cryosurgery 
plasma cytokine levels, IL-1α and TNF-α, rise significantly. These findings are in accordance with other 
studies describing an elevation of pro-inflammatory cytokines after cryosurgery. An increase in IL-6 
and TNF-α plasma levels is observed in patients treated with liver tumors treated by cryosurgery 
25. In an animal model an increase in NF-κB factor activation and NF-κB dependent cytokines after 
cryosurgery of normal liver tissue is described, resulting in a systemic inflammatory reaction leading 
to lung injury 26. This inflammatory response, as represented by elevated cytokines, could be a possible 
explanation for the anti-tumor response in animal tumor models after cryosurgery.
The purpose of this study was to investigate whether augmentation of the inflammatory response 
could lead to an extra inhibition of tumor growth. For many years LPS is known for its activation 
of inflammatory processes and its anti-tumor response in animal tumor models 27-29. After LPS 
administration TNF is produced by LPS-stimulated macrophages which, together with many other 
pro-inflammatory cytokines, is involved in inflammatory and anti-tumor responses 30-33. In this cascade 
IL-10 has an anti-inflammatory activity.
In the present study we have administered LPS at two different time points after surgical treatment 
of the primary tumor. In animals treated by cryosurgery LPS injection did not lead to extra growth 
inhibition of the secondary tumor. In animals treated by excision, however, a growth inhibition of the 
secondary tumor did occur, almost the same as in animals treated by cryosurgery alone (Fig 1). These 
data suggest that animals treated by cryosurgery are resistant to the possible inflammatory and anti-
tumor effects of LPS while in animals treated by excision this response can still be provoked.
The hypothesis of LPS tolerance after cryosurgery was strengthened by dose response studies. High 
doses of LPS administered 2 days after surgical treatment of the primary tumor led to high cytokine 
levels and gross mortality in the animals treated by excision while animals treated by cryosurgery 
seemed resistant to the (lethal) effects of LPS. Endotoxin tolerance is a well known feature which 
occurs when boost injections of LPS are administered to animals which have been primed with LPS 
before 34. In our experiments mice were primed by the cryosurgical treatment leading to endotoxin 
tolerance. Hence a boost of LPS 2 days after cryosurgery did not result in a strong inflammatory 
response. In contrast when LPS was given in non-lethal doses at the same time with cryosurgery this 
lead to a strong inflammatory response followed by death in most of the animals. This observation 
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resembles the clinical phenomenon of cryoshock, a syndrome of multi organ failure, coagulaopathy and 
disseminated intravascular clotting without signs of systemic sepsis 35. Apparently the inflammatory 
response that occurs at the time of cryosurgery is strongly intensified by LPS administration leading 
to gross mortality after combined treatment.
Another mediator in inflammatory responses is the anti-inflammatory cytokine IL-10. In a further 
attempt to augment the inflammatory response we have administered anti-IL-10 in order to eliminate 
the suppressive effect of IL-10. Neither in animals treated by cryosurgery, nor in animals treated by 
excision, this lead to extra inhibition of secondary tumor growth. Most likely the effect of anti-IL-10 is 
far too specific to evidently alter or enhance a response mediated by several different cytokines.
In conclusion, this study shows that cryosurgery leads to a rapid inflammatory response mediated by 
cytokines like TNF-α and IL-1α. Furthermore, cryosurgery can lead to endotoxin tolerance a few days 
after treatment. On the other hand animals are extremely sensitive to low dose LPS at the time of 
cryosurgery, resembling the clinical phenomenon known as cryoshock.
Although the anti-tumor response as seen in this and earlier studies can be explained by an aspecific 
inflammatory immune response, our results indicate that the enhancement of this aspecific 
inflammatory response will be difficult after cryosurgery, due to the induced tolerance in this pathway. 
In order to enhance an anti-tumor response after cryosurgery in a clinical setting, it seems preferable 
to induce a more tumor specific response, as can be mediated by T-cells. Future studies will focus on 
the appearance of this more specific response after cryosurgery.
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Colorectal cancer is a leading cause of morbidity and mortality in both men and women worldwide. 
Up to 40 percent of patients will eventually develop metastases. The liver is the most affected organ 
when metastatic disease is concerned but also pulmonary metastases are frequently observed.
In only 15% of people with colorectal metastases resection of hepatic metastases with curative 
intend is possible. The group of patients with only pulmonary metastases without any other signs 
of disease is even smaller. The question rises whether people with unresectable hepatic disease can 
be offered nothing else but chemotherapy. Moreover with more effective cytotoxic chemotherapy 
and monoclonal antibodies median survival has prolonged and another question comes up whether 
alternative treatments have the same survival benefits, complication rates and patient satisfaction.
In situ ablative techniques have been used for decades, but with the development of better technical 
equipment and intra-operative monitoring they have gained more and more interest. Cryosurgical 
and radiofrequency ablation of hepatic metastases have been the most popular ablative techniques. 
In selected groups of patients survival benefits with acceptable complication rates are frequently 
described. With better treatment modalities, and also more sensitive screening for metastases, the 
group of patients eligible for metastatic surgery seems to increase. And after liver surgery another 
issue occurs: Is it justified to perform thoracotomies for pulmonary metastases in patients with earlier 
resections and/or ablation of hepatic colorectal metastases?
Next to the assumed survival benefit there is another interesting phenomenon in ablative techniques. 
Does the ablated tumor tissue give rise to an immunological anti-tumor response? For example after 
cryosurgery of prostate carcinoma reduction of pulmonary metastases was observed. It would be 
interesting to understand this possible anti-tumor reaction in order to influence and even enhance it 
as part of a “cryo- or RFA immunotherapy”. 
This thesis has focused on the treatment of colorectal liver metastases especially with cryosurgery 
and RFA. An extensive description of both techniques is given together with the results of our own 
patient population. Next to that an evaluation is made of people with irresectable disease treated by 
ablation or chemotherapy. Also a unique group of patients is described who underwent pulmonary 
resection of colorectal metastases after former hepatic resection or ablation. In conclusion some 
results are presented on the antitumor effects of cryosurgery in an animal model.
Chapter 1 opens with a short introduction and outline of this thesis. In chapter 2 an overview of 
cryosurgery for colorectal hepatic metastases is given. A description of the technique, its results and 
complications is given. It seems that there is a survival benefit for patients treated by cryosurgery as 
compared to patients with irresectable disease who received chemotherapy only. However it must 
be recognized that a true comparison is difficult to make due to patient selection. Also the use of 
another, possible more attractive ablative technique, RFA, is already highlighted.
In recent years RFA has been the most popular in situ ablative technique. The reason for this is to 
conclude from chapter 3. In an extensive review on RFA for colorectal metastases the technique is 
further explained. The history of radiofrequency ablation with its technical background is discussed. 
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RFA can be performed percutaneously, by laparoscopy or open surgery and of each procedure 
advantages and disadvantages are mentioned. Most recent literature is reviewed on disease free and 
overall survival. Again the problem of patient selection and the lack of uniformity in most studies 
makes interpreting these figures difficult.
Like cryosurgery also RFA seems to prolong overall survival. As compared to cryosurgery RFA has less 
complications and is easier to perform. It seems that RFA has totally taken the place of cryosurgery. 
With these figures in mind it is unlikely that the mechanical ablation of liver metastases by cold 
application will revive in the near future. However other ablative techniques using laser and especially 
ultrasound could be of more interest in the next years. 
Also the question whether RFA could be performed in case of resectable hepatic lesions is addressed. 
Until now resection remains the gold standard and the need for randomized trials in order to define 
the exact role of RFA is emphasized. At the moment a trial comparing chemotherapy with RFA is 
ongoing. It will be more difficult to organize a trial in which resectable lesions are treated by RFA (or 
surgery). Until now there is no place for treatment of resectable lesions by ablative techniques, but 
there is a call from RFA proponents to start such a trial. Some inclusion criteria should be: resectable 
lesions smaller than 3 cm, RFA performed in open procedures (not percutaneously) and surgeons 
experience over 50 procedures. Earlier attempts to start comparable trials failed due to poor patient 
accrual. 
In chapter 4 the results of our patients treated with cryoablation are described. A group of 30 
patients with irresectable liver metastases is treated by cryosurgery with or without hepatic resection. 
Morbidity after cryosurgery was 26%. Myocardial infarction, pneumonia, abscess formation in the 
cryoablated lesion, and hemorrhage were observed. Local recurrence at the ablation site occurred 
in 6 of 30 patients. A median survival of 32 months is described which is favorable when compared 
to figures after chemotherapy only. Although it should be mentioned that patients with more than 
ten metastasis and extrahepatic disease were not eligible for cryosurgery. Compared with other 
cryosurgery data these results are similar and complications rates and survival rates also acceptable 
as compared to chemotherapeutic regimens. But as already mentioned the “glory days“ of cryosurgery 
are over as other ablative techniques have emerged with better complication rates and similar overall 
and disease free survival.
In the late 1990’s RFA was introduced in our clinic and replaced cryosurgery as the ablative technique in 
colorectal liver metastases. In chapter 5 a comparison is made between patients treated by cryosurgery 
and patients who underwent RFA. There were no significant differences in overall and disease free 
survival between the two techniques. The most striking difference was that after cryoablation the 
complication rate was much higher than after RFA. Local recurrence was equal between both groups. 
However in the cryoablation group significantly more people with metastases over 4 cm diameter 
were treated. It is well known that local recurrence is proportional with the diameter of the ablated 
lesions. An interesting observation in this study was that local recurrence after three months was 
better detected by FDG-PET than by CT scanning. All together both cryosurgical ablation as well 
as RFA seem to be effective in the treatment of irresectable colorectal metastases but due to lower 
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complication rate and easier application in favor of RFA, probably this will be the technique of choice 
in the near future. 
In our studies we describe RFA performed during open procedure. A great advantage of local ablative 
techniques is the possibility of percutaneous application. Until now results of percutaneous RFA are 
inferior, although there still is debate between percutaneous proponents, mainly radiologists, and 
advocates of open procedures, surgeons. The advantages of percutaneous RFA are obvious and when 
results are similar to those of open procedures and randomized trials can show it is equivalent also in 
case of resectable metastases, this will be the technique of choice. 
Before the introduction of local ablative techniques all patients with irresectable liver disease were 
candidate for chemotherapy. Until several years ago 5-FU/leucovorin was the only regimen with a small 
benefit on overall survival. However, with the introduction of new cytotoxic agents like irinotecan 
and oxaliplatin, together with the development of monoclonal antibodies, the median survival of 
patients with liver metastases has increased up to 20 months. Do cryosurgery and RFA really make 
a difference in overall survival? In chapter 6 a comparison is made between chemotherapy and 
local tumor ablation. All patients eligible for laparotomy in case of hepatic metastases were either 
treated by resection, local tumor ablation in case of irresectable disease and chemotherapy in case 
of irresectable disease which could not be treated by ablation due to technical considerations. Two 
and 5-years survival were 56 and 27% respectively for the local ablation group and 51 and 15% for 
the chemotherapy group. Median disease free survival in the local ablation group was 9 months. 
There was no significant difference in overall survival, but the 9 months disease free survival suggests 
a beneficial effect of local tumor ablation. Moreover compared with systemic chemotherapy more 
quality adjusted life years were gained after local ablative therapy. In a time of evidence based 
medicine the results of this study are the best available, but underline the need for randomized 
controlled trials. At the moment one EORTC trial is ongoing. This randomized phase II trial is studying 
combination chemotherapy, bevacizumab, and radiofrequency ablation to see how well they work 
compared to combination chemotherapy and bevacizumab alone in treating unresectable liver 
metastases in patients with colorectal cancer.
Some patients who underwent hepatic resection and/or tumor ablation will develop pulmonary 
metastases. We identified a group of 21 patients and compared their results after pulmonary resection 
with 18 people who had pulmonary metastasectomy without prior hepatic colorectal disease. The 
results are described in chapter 7. Disease free and overall survival are comparable in both groups. It 
seems that also after earlier hepatic surgery pulmonary metastasectomy can lead to an improvement 
of survival in a selected group of patients. An interesting development in pulmonary metastases 
surgery is the introduction of local ablative techniques i.e. RFA. In case of patients unfit or reluctant 
to undergo (re-)thoracotomy RFA can offer an alternative “metastasectomy”. Until now there are not 
much data on the treatment of RFA in case of pulmonary metastases of colorectal origin, but several 
centers have started with this treatment modality and first results are promising. An important factor 
to take into account is patients refusal of surgery and/or preference for percutaneous RFA. Especially 
patients with pulmonary metastases mostly have undergone multiple surgical procedures (colorectal, 
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liver and sometimes already thoracotomy) and are somehow reluctant to new major surgical 
interventions. With the introduction of percutaneous RFA of pulmonary metastases a reasonable 
alternative seems available.
The last two chapters of this thesis show the results of some experimental work on the possible anti-
tumor effect of cryosurgery. In the early days of cryoablation a possible antitumor effect was attributed 
to this treatment with the observation that pulmonary metastases diminished after cryoablation of 
prostate carcinoma. In order to gain more insight in the effects of cryosurgery we developed an 
experimental animal model. In chapter 8 we describe inhibition of secondary and metastatic tumor 
growth in a mouse model after cryoablation of a primary tumor. In the first hours after cryosurgery 
a significant increase in plasma IL-1α and TNF-α levels was observed which can probably attribute 
to the anti-tumor effect. In chapter 9 we try to enhance this antitumor effect. In the same mouse 
model lipopolysaccharides (LPS) are administered together with treatment and on several days after 
treatment. Again cryosurgery leads to an immediate inflammatory response. LPS administered two 
days after cryosurgery did not lead to a prolonged anti-tumor response. It seems that animals become 
endotoxin tolerant. On the other hand when LPS is given together with cryosurgical treatment an 
significant increase in mortality was noticed. This resembles the clinical phenomenon of cryoshock. 
This is a syndrome of multi-organ failure which can occur after cryosurgery an is potentially lethal. 
In our studies we did not describe the effect on secondary tumor grow after RFA. There are authors 
showing growth of residual hepatic tumor after radiofrequency ablation, while other groups report 
an increase in residual tumor growth after hepatic resection but not after RFA. 
It seems plausible that our observed anti-tumor effect is due to an aspecific inflammatory response. It 
is difficult to transfer these results to a clinical setting, but they give rise to further investigation of the 
responses after in situ tumor ablation and focus on a more tumor specific reaction. In continuation of 
our first experimental work our colleagues of the tumor immunology department have already made 
some exciting progress in modulating the antitumor response after in situ ablative techniques. After 
RFA and cryoablation tumor antigens are detectable. This anti-tumor response can be enhanced by 
administration of blocking antibodies. These experimental results show that in situ tumor ablation 
together with immune modulation leads to an ”in situ dendritic cell vaccination”. Although premature, 
this kind of anti-tumor regulation could also be applicable in a clinical setting. 
Altogether the results in this thesis show very acceptable results of in situ tumor ablation in case 
of irresectable disease. Until now the role of ablative techniques in resectable disease remains 
uncertain. With a growing population of patients with metastatic disease the need for tailored therapy 
is only growing. RFA and other ablative techniques can play an important and substantial part in this 
treatment. Especially when these anti-tumor effects can be translated to the clinical field, in situ 
ablation is even more promising and could have great therapeutic potential. But still there are a lot of 
blanks to fill in, which requires investigation and collaboration between different fields of medicine 
like surgery, radiology, medical oncology and immunology. 
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Colon- en rectumcarcinomen veroorzaken een aanzienlijk deel van de aan kanker gerelateerde ziekte 
en sterfte. Ongeveer 40 procent van de patiënten ontwikkelt uiteindelijk levermetastasen. Naast 
levermetastasen komen ook longmetastasen regelmatig voor.
Slechts 15 tot 20 procent van de patiënten met levermetastasen komt in aanmerking voor een opzet 
curatieve resectie. 
Is voor de overige 80% van de patiënten geen andere therapie voor handen dan chemotherapie? 
Daarbij dient gezegd te worden dat met de ontwikkeling van meer effectieve cytotoxische middelen 
en monoclonale antilichamen de overleving aanzienlijk is verbeterd en de vraag rijst of andere 
therapeutische opties leiden tot dezelfde overleving, complicatiegetallen en patiënttevredenheid?
Locale ablatieve technieken zijn al tientallen jaren in gebruik, maar met de komst van betere apparatuur 
en technieken zijn ze meer en meer in de aandacht gekomen. Cryo- en radiofrequente ablatie 
zijn tot nu toe de meest populaire modaliteiten. In geselecteerde groepen patiënten leiden beide 
technieken tot winst in overleving met een zeer acceptabel aantal complicaties. Met de voortgaande 
ontwikkeling van apparatuur en meer verfijnde detectie van metastasen, samen met een toenemend 
aantal van colorectale carcinomen, is de verwachting dat het aantal mensen dat in aanmerking komt 
voor een dergelijke behandeling in de komende jaren zal toenemen. Daarnaast ontstaat er een groep 
patiënten die na behandeling van levermetastasen nieuwe metastasen ontwikkelt in lever en/of 
longen. Heeft het zin longresecties te verrichten bij mensen die eerder resectie van levermetastasen 
hebben ondergaan?
Naast de mogelijke winst in overleving zou lokale tumorablatie nog andere interessante (bij-)werkingen 
kunnen hebben. Mogelijk kan de vernietigde kanker een immunologische antitumorreactie in gang 
zetten en zodoende dienen als een soort autovaccinatie. In de eerste publicaties over cryochirurgie bij 
prostaatcarcinomen werd een remmende werking op de groei van longmetastasen geconstateerd. Het 
is een uitdaging dit mogelijke antitumorfenomeen te begrijpen en eventueel te kunnen beïnvloeden 
en zodoende te komen tot een vorm van “cryo/RFA immunotherapie”.
In dit proefschrift wordt de behandeling van colorectale levermetastasen met cryotherapie en 
radiofrequente ablatie beschreven. Uitgebreid worden beide technieken geïntroduceerd samen met 
de resultaten van de door ons zelf behandelde patiënten. Eveneens wordt een unieke patiëntengroep 
beschreven met behandeling van zowel lever- als longmetastasen. Daarnaast volgt een beschrijving 
van de eerste dierexperimentele antitumoreffecten na cryoablatie van tumoren.
Hoofdstuk 1 begint met een korte introductie en uitleg over de inhoud en opzet van dit proefschrift. 
In hoofdstuk 2 volgt een overzicht over cryochirurgie bij colorectale levermetastasen. De techniek 
wordt beschreven, samen met de resultaten en complicaties. Deze behandeling lijkt een verbetering 
van de overleving te geven t.o.v. chemotherapie. Wel dient opgemerkt te worden dat dergelijke 
vergelijkingen moeilijk te maken zijn, omdat we te maken hebben met geselecteerde groepen 
patiënten. 
De meest populaire ablatieve techniek in de afgelopen jaren is RFA. In hoofdstuk 3 wordt duidelijk 
waarom dit zo is. In een uitgebreid samenvattend overzicht wordt deze techniek en resultaten ervan 
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beschreven. De geschiedenis van RFA met enige technische achtergronden worden vermeld. RFA 
kan zowel tijdens open-buik-chirurgie worden toegepast als laparoscopisch of percutaan. De meest 
recente literatuur wordt samengevat met betrekking tot ziektevrije en totale overleving. Ook hier is 
het moeilijk de resultaten te vergelijken doordat de studies erg heterogeen zijn en ook hier sprake 
is van geselecteerde patiëntengroepen. Ook RFA geeft een verbetering van de overleving en minder 
complicaties dan cryochirurgie. Dit is de belangrijkste reden dat RFA de plek van cryochirurgie heeft 
overgenomen. De ontwikkeling van andere lokale technieken (laser en ultrasone ablatie) biedt 
misschien interessante mogelijkheden in de toekomst. 
Ook wordt ingegaan op de vraag of RFA een plaats kan hebben in de behandeling van resectabele 
levermetastasen. Tot op heden blijft resectie de gouden standaard en zullen gerandomiseerde studies 
de exacte plaats van RFA moeten bepalen. Momenteel is een studie gaande welke de behandeling 
van levermetastasen met RFA vergelijkt met chemotherapie. Het heeft meer voeten in aarde een trial 
op te zetten waarin RFA vergeleken wordt met resectie, in het geval van resectabele metastasen. Tot 
dan is er geen plaats voor ablatie bij deze patiënten, maar de voorstanders van RFA vragen om een 
dergelijk onderzoek. Een dergelijke trial dient o.a. de volgende inclusiecriteria te bevatten: resectabele 
laesies kleiner dan 3 cm, RFA uitgevoerd tijdens open chirurgie (niet percutaan) en ervaring van de 
behandelaar (mogelijk meer dan 50 procedures). Eerdere pogingen een dergelijke trial in gang te 
krijgen zijn gestrand op de geringe patiënteninclusies.
In hoofdstuk 4 worden de resultaten van cryoablatie bij onze eigen patiënten beschreven. Dertig 
mensen werden behandeld met cryochirurgie al dan niet gecombineerd met resectie van de 
resectabele laesies. Er traden bij 26% van de patiënten complicaties op: o.a. hartinfarct, longontsteking, 
abcesvorming en bloedingen werden geconstateerd. Er was sprake van lokaal recidief bij 6 van de 
dertig mensen. De mediane overleving bedroeg 32 maanden, wat een winst is vergeleken met alleen 
chemotherapie. Hierbij moet wel vermeld worden dat patiënten met meer dan tien metastasen en 
metastasen buiten de lever werden uitgesloten van behandeling met cryoablatie. Onze resultaten 
zijn vergelijkbaar met andere studies. Toch lijkt cryochirurgie in de behandeling van (colorectale) 
levermetastasen zijn plaats voorgoed te hebben verloren aan behandelingen zoals RFA.
In de late jaren ’90 van vorige eeuw werd radiofrequente ablatie geïntroduceerd in onze kliniek. In 
hoofdstuk 5 word een vergelijking gemaakt tussen cryochirurgie en RFA bij de door ons behandelde 
patiënten. De overlevingsgetallen zijn identiek. Het belangrijkste verschil tussen beide technieken is 
het aantal complicaties. Bij cryochirurgie worden aanzienlijk meer complicaties gemeld dan bij RFA. 
Een verschil in lokaal recidief kon niet worden vastgesteld. Dit is in verscheidene andere studies 
wel het geval geweest, ten nadele van RFA. In onze studie waren in de cryochirurgiegroep wel meer 
patiënten met metastasen groter dan 4 cm. Hoe groter de laesies, hoe groter de kans op een lokaal 
recidief. 
Een interessante nevenbevinding in de studie is het feit dat de lokale recidieven binnen drie maanden 
beter werden ontdekt met FDG-PET scan dan met CT-scan. 
Al bij al kan uit dit artikel worden geconcludeerd dat zowel RFA als cryochirurgie effectief zijn als 
lokaal ablatieve therapie. Gezien het lagere aantal complicaties lijkt de voorkeur uit te gaan naar RFA, 
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mede ook door het feit dat de toepasbaarheid van deze techniek waarschijnlijk ook wat makkelijker 
is dan cryochirurgie.
In onze studie werd RFA altijd toegepast tijdens “open” chirurgie. Een groot voordeel van ablatieve 
technieken is de percutane toepasbaarheid. De resultaten van de percutane ablatie blijven echter nog 
wel wat achter, hoewel hierover nogal wat discussies gaande zijn tussen de verschillende voor- en 
tegenstanders. Echter het is duidelijk dat, wanneer de technieken dusdanig verbeteren dat percutane 
RFA dezelfde recidiefpercentages haalt als de open techniek, deze de voorkeur verdient. 
Voor de introductie van de ablatieve technieken bij de irresectabele levermetastasen was 
chemotherapie het enige alternatief. Tot enige jaren geleden was een regime met 5-FU/leucovorin 
de standaard behandeling met een geringe verbetering wat betreft totale overleving. Nadat nieuwe 
cytotoxische geneesmiddelen, als irinotecan en oxaliplatin en monoclonale antilichamen hun intrede 
deden verbeterde de totale mediane overleving naar ongeveer 20 maanden. Hebben cryochirurgie 
en RFA dan nog wel een toegevoegde waarde? In hoofdstuk 6 wordt een vergelijking gemaakt 
tussen chemotherapie en de lokaal ablatieve behandeling. Alle patiënten die een laparotomie konden 
aangaan vanwege colorectale levermetastasen werden behandeld met resectie als dit mogelijk was, 
kregen een lokaal ablatieve behandeling in geval van irresectabele metastasen en als dit technisch 
onmogelijk was werd chemotherapie gegeven. De twee- en vijf-jaarsoverleving waren 56 en 27% voor 
de lokale ablatieve groep en 51 en 15% voor de chemotherapiegroep. Er was geen significant verschil 
in totale overleving, maar een winst van 9 maanden in ziektevrije overleving in de lokale ablatieve 
groep t.o.v. chemotherapie suggereert hier toch een voordeel voor de lokale ablatieve technieken. 
Daarnaast werd bij de lokale ablatieve techniek een betere kwaliteit van leven geconstateerd dan bij 
chemotherapie. In een tijd van evidence based medicine is deze bewijslast dun, maar voorlopig wel 
het beste wat voorhanden is. Op dit moment is een EORTC- trial gaande waarin de behandeling van 
irresectabele colorectale metastasen met chemotherapie, bevacizumab en RFA vergeleken wordt met 
chemotherapie en bevacizumab. 
Een deel van de patiënten die behandeld is vanwege levermetastasen zal daarna ook longmetastasen 
ontwikkelen. We vergeleken een groep van 21 patiënten die zowel voor lever- als longmetastasen werd 
geopereerd met een groep van 18 mensen bij wie alleen longmetastasen werden geconstateerd en 
verwijderd. Deze resultaten staan beschreven in hoofdstuk 7. Ziektevrije en totale overleving waren 
vergelijkbaar in beide groepen. Ook na een eerdere hepatectomie kan pulmonale metastasechirurgie 
leiden tot een betere overleving. Uiteraard hebben we hier te maken met een geselecteerde groep 
patiënten. Een interessante ontwikkeling in de behandeling van pulmonale metastasen is ook hier 
de introductie van RFA als lokaal ablatieve alternatieve behandeling. De groep patiënten welke 
pulmonale metastasectomieën ondergaat heeft een uitgebreide chirurgische voorgeschiedenis. In 
geval van nieuwe longmetastasen wordt door velen een herhaalde thoracotomie zowel lichamelijk 
als geestelijk erg zwaar ervaren. RFA van longmetastasen kan percutaan zonder ernstige complicaties 
geschieden en biedt een reëel alternatief als patiënten geen chirurgische ingreep willen en/of kunnen 
ondergaan. 
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Chapter 11
In de laatste twee hoofdstukken van dit proefschrift worden de resultaten beschreven van enkele 
experimenten waarbij de mogelijke antitumoreffecten van lokale ablatieve technieken worden 
onderzocht. Nadat na de behandeling van prostaatcarcinomen met cryochirurgie longmetastasen in 
grootte afnamen werd de aandacht gevestigd op dit fenomeen. Om hierin meer inzicht te verkrijgen 
werd een proefdiermodel opgezet. In hoofdstuk 8 beschrijven we de remming van groei van een 
tweede tumor en metastasen na de behandeling van de eerste tumor met cryoablatie. In de eerste 
uren na cryochirurgie is er sprake van een verhoging van plasma IL-1α en TNFα, wat mogelijk een 
verklaring kan zijn voor dit antitumor effect. 
In hoofdstuk 9 werd geprobeerd dit antitumoreffect te versterken. In hetzelfde muismodel werd 
lipopolysaccharide (LPS) toegediend kort na tumorbehandeling. Ook hier liet cryochirurgie weer een 
acute ontstekingsreactie zien. Wanneer LPS wordt toegediend twee dagen na de initiële behandeling 
gebeurt er niets. De dieren lijken tolerant geworden voor het toch op zichzelf toxische LPS. Wanneer 
echter LPS wordt toegediend tegelijk met de cryochirurgische behandeling is de respons zo sterk dat 
er sprake is van een zeer hoge sterfte. Dit lijkt op het fenomeen wat ook in klinische toepassingen is 
beschreven als cryoshock. Een syndroom van multiorgaanfalen met een hoog mortaliteitscijfer. 
In deze studies hebben we niet het effect van RFA op een tweede tumor beschreven. Andere auteurs 
beschrijven verschillende resultaten. Zowel een uitgroei van metastasen na RFA als een versnelde 
uitgroei juist na resectie werd beschreven.
Het lijkt waarschijnlijk dat de door ons beschreven remmende werking op de groei van metastasen en 
tweede tumoren toe te schrijven is aan een aspecifieke ontstekingsreactie. Dit is moeilijk te vertalen 
naar de kliniek. Het geeft echter wel aanleiding meer gericht onderzoek te doen naar de reacties op in-
situ-ablatie, met de bedoeling een meer specifieke component te kunnen onderscheiden. Als vervolg 
op deze eerste experimenten hebben onze collega’s van de afdeling Tumor Immunologie al enkele 
fraaie artikelen gepubliceerd waarin de antitumor respons na in-situ-ablatie al enigszins gemoduleerd 
kan worden. Na RFA en cryochirurgie is tumorantigeen detecteerbaar. Deze antitumorreactie kan 
worden versterkt door toediening van blokkerende antilichamen. Deze experimenten hebben 
aangetoond dat in-situ-ablatie tezamen met immuunmodulatie kan leiden tot een soort “in-situ-
dendritische-cel-vaccinatie”. Hoewel enigszins prematuur zou een dergelijk fenomeen ook klinische 
toepasbaarheid kunnen hebben.
Samenvattend laat dit proefschrift zien dat irresectabele colorectale levermetastasen goed te 
behandelen zijn met in-situ-ablatieve technieken. De toekomst zal moeten uitwijzen of zij ook hun 
toepasbaarheid gaan hebben bij resectabele metastasen. Met een toenemend aantal van patiënten 
met behandelbare metastasen wordt het op maat aanbieden van een dergelijke therapie alleen maar 
interessanter. RFA en andere ablatieve technieken kunnen hier een belangrijke rol in spelen. Als 
daarnaast ook een soort van antitumorreactie kan worden opgewekt welke kan worden gemoduleerd, 
dan wordt in-situ-ablatie nog aantrekkelijker. Voor het zover is moet er echter nog veel werk verricht 
worden waarvoor zowel meer experimenteel alsook klinisch onderzoek nodig is. Hier blijft het 
zaak dat de verschillende betrokken disciplines als chirurgie, medische oncologie, immunologie en 
radiologie hun krachten bundelen.
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